

The Practice of Emergency Physicians Emergency Medicine Reports

2004 Subject Index included
with this issue.

Volume 26, Number 3

January 24, 2005

Neurologic emergencies of pregnancy range from life-threatening conditions such as eclamptic seizures (see Hypertensive Disorders of Pregnancy, 2004;25:293-308) to self-limiting disorders like meralgia paresthetica. This discussion will include those neurologic disorders directly resulting from pregnancy or the puerperium, those that are pre-existing conditions but now affect the pregnant patient or are affected by the gravid state of the patient, and those disorders that are not directly related to the pregnancy but may first become apparent during the gravid state. Most of the diseases presented are not a primary emergency department (ED) problem, but rather may intersect the ED due to time of day, day of week, or lack of other health care access. All disorders covered in this section occur in the non-pregnant patient as well, and therefore it is assumed that readers will consult a detailed text for specifics if they are unfamiliar with the disorder. Where

appropriate, diagnostic pitfalls likely to present to the ED will be discussed.

—The Editor

Neurologic Complications of Pregnancy

A Systematic Approach to Patient Evaluation and Management

Author: **Mary Hughes, DO, FACEP, FACOEP**, Professor, Emergency Medicine, Michigan State University College of Osteopathic Medicine (MSU-COM); Program Director, MSU-COM Emergency Medicine Residency, East Lansing, MI.

Peer Reviewers: **Charles Emerman, MD**, Chairman, Emergency Medicine, Case Western Reserve University, Cleveland, OH; and **Gary Hals, MD, PhD**, Department of Emergency Medicine, Palmetto Richland Hospital, Columbia, SC.

Epilepsy and the Pregnant Patient

Of all pre-existing neurologic disorders in the pregnant patient, epilepsy is second only to migraines, affecting approximately 1:200 gravid patients, with a prevalence in the general population of 1%.^{1,4} In the ideal situation, each female of child-bearing age with epilepsy would be provided preconception vitamin and folic acid supplementation and counseling to decrease the risk of adverse events, including congenital anomalies, prior to becoming

pregnant.⁵ However, as greater than 50% of pregnancies are unplanned, pre-pregnancy counseling is lacking in many if not most epileptic females.^{2,6} This partially is explained by the drug/drug interaction between the enzyme-inducing anti-epileptic drugs (barbiturates, phenytoin, carbamazepine, topiramate, and

EDITOR IN CHIEF

Gideon Bosker, MD
Special Clinical Projects and Medical Education Resources
Assistant Clinical Professor
Section of Emergency Services
Yale University School of Medicine
Associate Clinical Professor
Oregon Health Sciences University

EDITORIAL BOARD

Paul S. Auerbach, MD, MS, FACEP
Clinical Professor of Surgery
Division of Emergency Medicine
Department of Surgery
Stanford University School of Medicine
Stanford, California

Brooks F. Bock, MD, FACEP
Dayanandan Professor and Chairman
Department of Emergency Medicine
Detroit Receiving Hospital
Wayne State University
Detroit, Michigan

William J. Brady, MD, FACEP, FAAEM
Vice Chairman of Emergency Medicine and Associate Professor,
Department of Emergency Medicine,
Associate Professor of Internal Medicine and Program Director of Emergency Medicine Residency,
Department of Internal Medicine
University of Virginia School of Medicine
Charlottesville, Virginia

Kenneth H. Butler, DO
Associate Residency Director
University of Maryland Emergency Medicine Residency Program
University of Maryland School of Medicine
Baltimore, Maryland

Michael L. Coates, MD, MS
Professor and Chair
Department of Family and Community Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Alasdair K.T. Conn, MD
Chief of Emergency Services
Massachusetts General Hospital
Boston, Massachusetts

Charles L. Emerman, MD
Chairman
Department of Emergency Medicine
MetroHealth Medical Center
Cleveland Clinic Foundation
Cleveland, Ohio

James Hubler, MD, JD, FCLM, FAAEM, FACEP
Clinical Assistant Professor of Surgery
Department of Emergency Medicine
University of Illinois College of Medicine
at Peoria;
OSF Saint Francis Hospital
Peoria, Illinois

Kurt Kleinschmidt, MD, FACEP
Assistant Professor
University of Texas Southwestern Medical Center, Dallas
Associate Director
Department of Emergency Medicine
Parkland Memorial Hospital
Dallas, Texas

David A. Kramer, MD, FACEP, FAAEM
Program Director,
York Hospital Emergency Medicine Residency
Clinical Associate Professor
Department of Emergency Medicine
Penn State University
York, Pennsylvania

Larry B. Mellick, MD, MS, FAAP, FACEP
Vice Chairman for Academic Development and Research
Department of Emergency Medicine
Medical College of Georgia
Augusta, Georgia

Paul E. Pepe, MD, MPH, FACEP, FCCM
Professor and Chairman
Division of Emergency Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Charles V. Pollack, MA, MD, FACEP
Chairman, Department of Emergency Medicine, Pennsylvania Hospital
Associate Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Robert Powers, MD, MPH, FACP
Chief and Professor, Emergency Medicine
University of Connecticut
School of Medicine
Farmington, Connecticut

David J. Robinson, MD, MS, FACEP
Research Director
Department of Emergency Medicine
The University of Texas – Health Science Center at Houston
Director, Diagnostic Observation Center
Memorial Hermann Hospital
Houston, Texas

Steven G. Rothrock, MD, FACEP, FAAP
Professor of Emergency Medicine
University of Florida College of Medicine,
Department of Emergency Medicine
Orlando Regional Medical Center
Orlando, Florida

Barry H. Rumack, MD
Director, Emeritus
Rocky Mountain Poison and Drug Center
Clinical Professor of Pediatrics
University of Colorado Health Sciences Center
Denver, Colorado

Richard Salluzzo, MD, FACEP
Chief Executive Officer and Chief Medical Officer
Conemaugh Health System
Johnstown, Pennsylvania

Sandra M. Schneider, MD
Professor and Chair
Department of Emergency Medicine
University of Rochester School of Medicine
Rochester, New York

John A. Schriver, MD
Chief, Section of Emergency Medicine
Yale University School of Medicine
New Haven, Connecticut

David Sklar, MD, FACEP
Professor and Chair
Department of Emergency Medicine
University of New Mexico School of Medicine
Albuquerque, New Mexico

Corey M. Slovis, MD, FACP, FACEP
Professor and Chairman
Department of Emergency Medicine
Vanderbilt University School of Medicine,
Medical Director
Metro Nashville EMS
Nashville, Tennessee

J. Stephan Stapezynski, MD
Chair
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Charles E. Stewart, MD, FACEP
Emergency Physician
Colorado Springs, Colorado

Gregory A. Volturo, MD, FACEP
Professor of Emergency Medicine and Medicine
Vice Chair, Department of Emergency Medicine
University of Massachusetts Medical School
Worcester, Massachusetts

Albert C. Wehl, MD
Assistant Professor of Medicine and Surgery
Department of Surgery
Section of Emergency Medicine
Yale University School of Medicine
New Haven, Connecticut

Steven M. Winograd, MD, FACEP
Attending Physician
Emergency Department
Adena Regional Medical Center
Chillicothe, Ohio

Allan B. Wolfson, MD, FACEP, FACP
Program Director,
Affiliated Residency in Emergency Medicine
Professor of Emergency Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

© 2005 Thomson American Health Consultants. All rights reserved.

tiagabine) and oral contraceptives (OC). They act by increasing the metabolism of the OC, making the OC less effective.⁷

Seizure control varies in pregnancy, with approximately one-third of patients having an increase in activity. Poor pre-pregnancy control predicts pregnancy control in many cases.² There are several reasons for this increased seizure frequency, including lack of compliance (often associated with withholding of med-

Emergency Medicine Reports™ (ISSN 0746-2506) is published biweekly by Thomson American Health Consultants, 3525 Piedmont Road, N.E., Six Piedmont Center, Suite 400, Atlanta, GA 30305. Telephone: (800) 688-2421 or (404) 262-7436.

Vice President/Group Publisher: Brenda Mooney
Editorial Group Head: Glen Harris
Specialty Editor: Shelly Morrow Mark
Marketing Manager: Nan Reeves
GST Registration No.: R128870672

Periodicals postage paid at Atlanta, GA. **POSTMASTER:** Send address changes to **Emergency Medicine Reports**, P.O. Box 740059, Atlanta, GA 30374.

Copyright © 2005 by Thomson American Health Consultants, Atlanta, GA. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Back issues: \$31. Missing issues will be fulfilled by customer service free of charge when contacted within one month of the missing issue's date.

Multiple copy prices: One to nine additional copies, \$359 each; 10 to 20 additional copies, \$319 each.

Accreditation

Emergency Medicine Reports™ continuing education materials are sponsored and supervised by Thomson American Health Consultants. Thomson American Health Consultants designates this continuing education activity for up to 60 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.

Emergency Medicine Reports™ also is approved by the American College of Emergency Physicians for 60 hours of ACEP Category 1 credit. **Emergency Medicine Reports** has been reviewed by the American Academy of Family Physicians as having educational content acceptable for Prescribed credit hours. This volume has

THOMSON
★
AMERICAN HEALTH CONSULTANTS

Statement of Financial Disclosure

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Emerman (peer reviewer) is a consultant for Aventis and Scios; serves on the speaker's bureau for Scios, Aventis, Sepracor, Pfizer, Astra-Zeneca, and Roche; and has received research grants from Aventis, Scios, and Sepracor. Drs. Hughes (author) and Hals (peer reviewer) report no relationships with companies related to the field of study covered by this CME program. Dr. Bosker (editor) has been compensated for speaking engagements and/or editorial services related to production of peer-reviewed Clinical Consensus Reports® under the auspices of unrestricted educational grants for Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Roche Pharmaceuticals, Bayer, Novartis, Forest Pharmaceuticas, and Schering Plough Corporation. Dr. Bosker also acknowledges that he has received royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and/or other electronic or print materials to the following pharmaceutical companies: Pfizer, Sanofi-Aventis, Bayer, Roche, Forest Laboratories, and Novartis. He is a minor stockholder in Pfizer. Any other stock ownership which he may have in other pharmaceutical companies is managed in blinded fashion by an independent consultant without Dr. Bosker's input or consultation.

This publication does not receive commercial support.

Subscriber Information

Customer Service: 1-800-688-2421

Customer Service E-Mail: customerservice@ahcpub.com
Editorial E-Mail: shelly.mark@thomson.com

World Wide Web page: <http://www.ahcpub.com>

Subscription Prices

1 year with 60 ACEP/60 AMA/60 AAFP

Category 1/Prescribed credits: \$544

1 year without credit: \$399

Resident's rate \$199

All prices U.S. only.

U.S. possessions and Canada, add \$30 plus applicable GST. Other international orders, add \$30.

been approved for up to 60 Prescribed credit hours. Term of approval covers issues published within one year from the beginning distribution date of 1/05. Credit may be claimed for one year from the date of this issue. Thomson American Health Consultants (AHC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This is an educational publication designed to present scientific information and opinion to health professionals, to stimulate thought, and further investigation. It does not provide advice regarding medical diagnosis or treatment for any individual case. It is not intended for use by the layman. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. Clinical, legal, tax, and other comments are offered for general guidance only; professional counsel should be sought for specific situations.

This CME activity is intended for emergency physicians. It is in effect for 36 months from the date of the publication.

For Customer Service and CME questions,

Please call our customer service department at (800) 688-2421. For editorial questions or comments, please contact **Shelly Morrow Mark**, Specialty Editor, at shelly.mark@thomson.com.

ications by the mother to decrease the risk for congenital anomalies early in pregnancy), nausea and vomiting associated with pregnancy that limits intake and retention of medications, changes in intestinal absorption, increased clearance rates of anti-epileptic drugs, and changes in protein binding sites.³ Because of changes in albumin and protein binding sites, the ideal way to monitor anti-epileptic drug therapy is to obtain a free blood level of the anti-epileptic drug pre-pregnancy, and then maintain this level during the pregnancy, assuming good seizure control pre-gestation.^{3,5} The poorly controlled patient is the most likely patient to present to the ED, and measuring free drug concentrations in these patients may assist in the achievement of better control.^{5,8}

Adverse Outcomes and Congenital Abnormalities in the Children of Women with Epilepsy

More than 90% of pregnant patients on anti-epileptic drugs will have a favorable fetal outcome,^{8,9} but the incidence of congenital malformations in infants born to mothers on anti-epileptic drugs is 4-8%, which is 2-3 times the baseline rate.^{2,4,10,11} The majority of malformations occur in the first trimester, often before the mother is even aware of her pregnant state.¹² Fetal anticonvulsant syndrome has been described with virtually all anti-epileptic drugs and is a term used to describe a constellation of major and minor anomalies that occur in infants born to mothers receiving anti-epileptic drugs.¹³ The most common major fetal malformations due to anti-epileptic drugs include cleft lip/palate, congenital heart defects including Tetralogy of Fallot and atrial or ventricular septal defects, neural tube defects that often are open, and genitourinary defects.⁷ Any patient newly diagnosed as pregnant in the ED who is noted to be on an anti-epileptic drug for any medical reason, including non-seizure related diagnoses, should be referred back to her treating physician for reevaluation and close monitoring to decrease the risk of these adverse events. Alteration of stable anti-seizure medication regimens by the ED physician is not indicated, but phone consultation with the prescribing physician to notify him or her of the pregnancy status of the patient and arrange for follow-up is. The lowest effective dose of the least number of medications while still maintaining adequate seizure control is the goal.

Although the newer anti-epileptic drugs, gabapentin (Neurontin), lamotrigine (Lamictal), and felbamate (Felbatol) have not been extensively studied, the five major anti-epileptic drugs, namely phenytoin (Dilantin), carbamazepine (Tegretol), phenobarbital (Luminal), primidone (Mysoline), valproic acid (Depakene, Depakote), have been. All have been associated with an increased risk of malformations, especially in patients on polytherapy with high anti-epileptic drug levels.^{2,14} Ideally the patient should be placed on the least toxic monotherapy possible.¹⁵ However, changing anti-epileptic drug therapy after 10 weeks gestation to alter side effect profiles will not change the final pregnancy outcome of birth defects, and therefore is not warranted. This is because all anti-epileptic drugs that cause fetal anomalies will do so during the organogenesis that occurs in the first 10 weeks, often well before the patient realizes she is pregnant.¹⁶ Again,

90% of all patients on anti-epileptic medications will have a favorable fetal outcome,⁹ and there is a 10-fold increase in maternal mortality in patients who suffer a seizure while pregnant.¹⁷ The Gabapentin Pregnancy Registry has reported on 51 fetuses exposed to the drug during gestation for any reason, including epilepsy. To date, there is no increased risk above the general population in fetal malformations or maternal complications. Caution should be used, however, because the number of studied patients is small.¹⁸ A history of maternal epilepsy without the concomitant use of anti-epileptic drugs is not associated with a greater frequency of congenital malformations.^{14,19}

Patients who suffer a seizure during their pregnancy, regardless of the presence or absence of anti-epileptic drugs, may have an increased risk of congenital abnormalities or other pregnancy-related complications that may be the result of hypoxia, acidosis, or trauma during the seizure. A study conducted in Finland did not show an increase in fetal malformations in women who suffered a grand mal seizure during the first trimester.²⁰ However, a study in the United Kingdom of maternal mortality from 1985-1999, noted a 10-fold increase in mortality in women with epilepsy when compared to those without. Epilepsy was the third leading cause of maternal death, behind cardiac deaths and stroke. Most of these deaths were seizure related, and often in women who discovered they were pregnant, discontinued their anti-epileptic medication, and then suffered a seizure. Seizure medications should not be changed in the ED.¹⁷

Trauma during a seizure may cause abruptio placenta, premature rupture of membranes, premature delivery, or fetal demise.²¹ These facts should be communicated to the female patient who is non-compliant secondary to worries about effects of anti-epileptic drugs on her fetus. For the pregnant patient prior to 20 weeks gestation, although the fetus is non-viable, the potential for these complications should be explicitly documented, and the mother should be instructed to contact her obstetrician should she experience a sudden leak of fluids, abdominal pain, vaginal bleeding, or a spontaneous abortion. If any of these occur and the mother is unable to contact her obstetrician, she should be instructed to return to the ED for re-evaluation. For any pregnant patient past 20 weeks gestation who suffers a seizure, these complications must be ruled out, which often necessitates the observation of the mother and fetus for several hours in an obstetrical observation ward or the ED if no such space is available. In addition, any seizure that occurs past 20 weeks gestation, even in a known epileptic patient, should prompt an evaluation for eclampsia. In all cases except maternal allergy, benzodiazepines are the drug of choice for acute control regardless of etiology.³

Nutritional Recommendations

Folic Acid. Folic acid is involved in the process of closure of the neural tube and development of red and white blood cells.²² Supplementation in the periconceptual time period is recommended for the female of childbearing age, with higher doses recommended for those with a prior history of an infant with a neural tube defect.^{7,22} Folates are cofactors in many biochemical reactions, including one-carbon metabolism. Barbiturates, carba-

mazepine, valproic acid, and phenytoin interfere with folic acid metabolism, and the enzyme inducing anti-epileptic drugs (barbiturates, phenytoin, carbamazepine, topiramate, and tiagabine) decreases absorption. Any of the anti-epileptic medications that induce the cytochrome p450 system can lower plasma folate levels as well.¹⁷ The recommended dose for folic acid in patients receiving anti-epileptic drugs is 10 times the dose (4 mg daily) of that recommended to women not on anti-epileptic drugs (0.4 mg daily). This should be started at the time of the first diagnosis of pregnancy, even if that occurs in the ED, unless obstetrical consultation can be obtained within the following 24 hours.^{3,5} Doses greater than 5 mg daily may impair seizure control and lower serum phenytoin levels.²³⁻²⁵ Even with the larger doses given to women on anti-epileptic drugs, especially those taking valproic acid or carbamazepine, supplementation has had less than expected results in neural tube defect prevention, although all studies to date have been quite small.^{7,22}

Vitamin K. All commonly used anti-epileptic drugs except valproic acid and clonazepam (Klonopin) can decrease the fetal vitamin K dependent clotting factors, leading to an increased risk of neonatal hemorrhage. It is recommended by the American Academy of Neurology⁴ that oral vitamin K should be administered to the mother during the last month of gestation at a dose of 10 mg daily. If this has not been done and the patient presents for delivery, 10 mg of vitamin K may be given IV during delivery. The newborn also should receive 1 mg IM of vitamin K. Fresh frozen plasma may be necessary to manage hemorrhagic complications.^{1-3,5,7,12,16} A more recent study questions the need for oral supplementation for the final month of pregnancy and did not note an increased risk of hemorrhagic events in newborns born to mothers not receiving supplemental vitamin K, but was underpowered to evaluate the true risk of hemorrhage in those infants born to mothers on anti-epileptic drugs.²⁶ It is a current recommendation by the American Academy of Pediatrics that all newborns receive 0.5-1.0 mg of vitamin K IM immediately after delivery.¹⁶ This includes infants born to mothers on anti-epileptic medications.

Neonatal Exposure. Finally, the neonate exposed to phenobarbital or primidone (whose active metabolite is phenobarbital) may present approximately one week post-delivery with signs and symptoms of phenobarbital withdrawal, which may last for months.^{12,27} Withdrawal symptoms include hyperexcitability, irritability, and regurgitation.¹ This should be one of the many items on the differential of the irritable newborn with a history of maternal gestational phenobarbital use, and following a complete work-up may be the diagnosis of exclusion.

ED Management of the Possibly Pregnant Seizing Patient

The management of the female patient presenting to the ED with a new-onset seizure should follow standard therapy and is beyond the scope of this article. Oxygen and benzodiazepines should be used for immediate control. The seizure evaluation, including a pregnancy test, serum chemistries, urine drug screen and dip for protein, head computed tomography (CT) scan, and

possibly magnetic resonance imaging (MRI) or lumbar puncture should be completed if indicated, regardless of the results of the pregnancy test. If the patient is found to be gravid, an ultrasound should follow a quantitative HCG level to determine the fetal age and viability. If the fetus is determined to be greater than 20 weeks or the patient is within two weeks post-partum, then eclampsia must be included in the differential, and magnesium sulfate started to prevent further seizures. In addition, fetal and maternal monitoring should be conducted following the seizure, preferably in an obstetrical observation unit equipped to handle an imminent delivery if necessary.

Summary

The ED physician who is presented with a pregnant or newly delivered patient suffering from a seizure, in addition to managing airway, breathing, and circulation (ABCs), should:

- Assess the mother for eclampsia if past 20 weeks gestation or within two weeks postpartum. (*See Hypertensive Disorders of Pregnancy, 2004;25:293-308.*)
- Provide oxygen therapy and place the patient in the left lateral position if pregnant and past 20 weeks.
- Treat the initial seizure, regardless of etiology, with benzodiazepines.
- Place the eclamptic patient on magnesium sulfate to prevent further seizures.
- If past 20 weeks gestation, monitor the mother and fetus for placental abruption, premature rupture of membranes, premature delivery, or fetal demise—this may require an observation period in the obstetrical unit depending on institutional protocols.
- If fewer than 20 weeks gestation, explain that the fetus is not viable outside the uterus, but that there are potential complications of the seizure that may occur, including: premature membrane rupture causing fluid leak; placental abruption, which may cause abdominal or pelvic pain or vaginal bleeding; spontaneous abortion; or stillbirth.
- Evaluate the new-onset seizure patient with the same diagnostic modalities that one would use if the patient were not pregnant, including CT of the head, drug screen, and possible MRI or lumbar puncture, depending on the scenario.
- Be aware that protein binding changes during pregnancy and free anti-epileptic drug levels are more accurate.
- Arrange follow-up with the physician managing the patient's seizures or other medical conditions being treated with anti-epileptic drugs to occur within the following few days, if the patient is found to be pregnant in the ED.
- Write a prescription for folic acid 4 mg daily until the patient can be seen by the neurologist and/or obstetrician in follow-up.
- Arrange obstetrical follow-up for the newly diagnosed patient on an urgent basis.
- If a pregnant patient on anti-epileptic drugs presents to the ED for delivery and cannot be taken to the labor and delivery floor, give vitamin K 10 mg IV to the mother and 1 mg IM to the infant at the time of birth, unless the mother has received vitamin K orally for the preceding month. In this case, give the infant the AAP recommended dose of vitamin K 1 mg IM.

Table 1. Patient Education for Women on Antiepileptic Drugs for Any Reason²⁸

- You have been diagnosed with pregnancy, and are noted to be on one of several anti-epileptic drugs.
 - If these medications are being taken for the management of epilepsy you should consult the health care provider managing your seizures.
 - If these medications are being taken for migraine prophylaxis or as a mood stabilizer, consult the health care provider managing these conditions.
 - Anti-epileptic drugs have been associated with an increased risk of birth defects in infants born to mothers who take them. These abnormalities occur during the first 10 weeks of your pregnancy.
 - This risk is 2-3 times that of the population not taking these medications. However, more than 90% of pregnancies that occur while the mother is taking one of these medications produce healthy newborns.
 - DO NOT stop taking these medications without consulting your physician, particularly if you are using them for seizure control. A seizure is also harmful to you and your baby. It may cause chemical imbalances in the blood, and trauma-related injuries to you or the baby may be fatal to one or both of you.
 - If you are not already doing so, DO begin taking folic acid. A prescription for 4 mg/day is being provided until you can visit the obstetrician.
 - DO arrange obstetrical follow up and follow their recommendations regarding the use of medications.
 - DO adjust your lifestyle to avoid known triggers for your seizures. This includes getting enough rest; avoiding illicit drugs, alcohol, cigarettes, and prolonged exposure to flashing lights from any source (i.e., video games, computer
-
- Document in the chart patient education regarding seizure disorders and pregnancy, and the use of anti-epileptic drugs during pregnancy. (*See Table 1.*)
 - In addition, the ED physician, when presented with an irritable newborn, should explore the medication list of the mother and include in the lengthy differential of this disorder possible withdrawal from maternal phenobarbital or mysoline.
 - Although the pregnant patient in status is rare, she should be treated in the same fashion as the non-pregnant status patient.

Stroke and Cerebral Venous Thrombosis

Introduction. As if pregnancy weren't fraught with enough potential disasters, the pregnant patient also is at increased risk for a cerebrovascular accident (CVA). Cerebrovascular disease in

pregnancy accounts for more than 12% of maternal deaths.²⁹ Two recent large studies have placed the incidence of stroke (non-hemorrhagic and hemorrhagic combined) at 8.9-26/100,000 deliveries, approximately twice the incidence for females of the same age who weren't pregnant.³⁰⁻³² In these studies, which controlled for the "referral center factor" if necessary, the greatest risk was in the first few weeks postpartum, with less of a risk during the pregnancy itself.³⁰ In his population-based study in the Washington, D.C. area, Kittner noted a 0.7 relative risk of ischemic stroke during pregnancy, which rose to an 8.7 relative risk postpartum. Likewise, the relative risk of intracerebral hemorrhage from any cause was 2.5 during pregnancy, and 28.3 in the postpartum period.³⁰ One study revealed a nearly equal incidence of hemorrhagic and non-hemorrhagic strokes,³² whereas others demonstrate a preponderance of ischemic (arterial and venous) events.^{30,31}

A greater percentage of ischemic cerebral infarctions in this patient population are arterial rather than venous, but combined account for up to 69% of CVAs in pregnancy.²⁹ Etiologies range from cardiac emboli and arterial dissections to coagulopathies. Peripartum cardiomyopathy, hypertension, diabetes, underlying cardiac disease, smoking, and thrombophilic conditions increase the risk for ischemic stroke. In addition, pregnancy itself induces a relative hypercoagulable state, increasing the patient's risk for a cerebral event.^{29,33}

The most common etiologies of hemorrhagic strokes include ruptured aneurysms, followed by arteriovenous malformation (AVM) and disseminated intravascular coagulopathy. Preeclampsia-eclampsia is an important cause of cerebral hemorrhage but not infarction.^{33,34} Overall, patients with hemorrhagic strokes have a higher mortality rate when compared to ischemic events in these more recent studies.^{31,32} A prior history of stroke does not preclude a subsequent pregnancy, and patients with a prior history of non-pregnancy related stroke have a 0-1% risk of a subsequent stroke during pregnancy. For patients with a thrombophilia, the recurrence rate is as high as 20%.^{33,35}

Diagnostic Evaluation for Suspected Strokes in the Pregnant Patient

The diagnostic workup for the pregnant patient with a suspected stroke should be the same as for the non-pregnant one. Initially, a thorough history and physical exam with attention to the blood pressure, the neurological examination including fundoscopic, the cardiovascular exam for rate and rhythm disturbances as well as murmurs, and the urine for drug screen as well as proteinuria should be conducted. The examination of the skin may reveal evidence of emboli or markers of connective tissue diseases.

A CT scan with abdominal shielding has minimal fetal exposure (2mRad).³⁶ Cerebral angiography with shielding is similar in skilled hands. Iodinated contrast may be given with good IV hydration, but poses a risk for fetal hypothyroidism if given after 6 months gestation. This easily is diagnosed and treated at birth if the initial benefit of the test in the mother outweighs the fetal risk.³⁶

MRI appears to be safe but has not been studied extensively, and gadolinium is an unknown risk, which should be avoided if

possible.³⁷⁻³⁹ The latest American College of Obstetrics and Gynecology recommendations published in 1995 advise against an MRI in the first trimester, but other more recent studies have not shown deleterious fetal effects.⁴⁰ In 2002, the American College of Radiology published a white paper on the safety of MRI. Their position is that any pregnant woman may undergo MRI regardless of pregnancy stage, providing a Level Two MR Personnel-designated attending radiologist believes the benefits outweigh the risks and no other non-ionizing means can be utilized to gain the information. In addition, the information gained must be needed to affect care of the mother and/or fetus during the pregnancy, and the referring physician does not feel that it is prudent to wait until the patient is post-partum. MR contrast agents should *not* be given routinely, and on a case-by-case basis the MR attending radiologist must feel the benefits outweigh the risk. The mother should sign an informed consent form.⁴¹ Therefore, it is recommended that the emergency physician discuss the benefits and risks of the study with the radiologist, patient's obstetrician, and the patient before ordering an MRI, especially if it is in the first trimester. Contrast should be avoided.⁴² It should be noted that several studies have been conducted on the evaluation of the fetus for defects utilizing MRI, but they generally are in the third trimester.⁴³⁻⁴⁵ Fortunately, the majority of the CVAs occur in the post-partum period, and thus carry no risk to the fetus from the MRI.

Determining the exact etiology of an ischemic event is paramount to providing the correct treatment, and this may necessitate studies outside the CNS, including electrocardiography and transesophageal echocardiography. Coagulation studies and a search for the common thrombophilias are indicated.³³

Cerebral Venous or Sinus Thrombosis

Cerebral venous thrombosis (CVT) is another vascular event that is more common in the pregnant than non-pregnant patient, with 80% of cases occurring in the second and third postpartum weeks.³⁷ However, the diagnosis often is difficult to make and generally requires an MRI or, occasionally, a cerebral angiogram to reach a definitive answer. The initial presentation is one of a headache and variable neurological findings depending on the venous system or sinus thrombosed, and often is accompanied by an elevated intracranial pressure and normal cerebrospinal fluid (CSF) studies. The absolute mortality is unknown, but is somewhat greater than 5% in developed countries, and reported as high as 30%.^{33,46} There appears to be a high prevalence of thrombophilia (up to 20% Factor V Leiden) in patients with CVT.³³

Current treatment of CVT includes heparin initially with anticoagulation continued for 2-3 months, anticonvulsants for patients who suffer seizures, and intracranial pressure lowering medications or procedures for those in which it is indicated.⁴⁶ In addition, dehydration should be avoided.³³ If the diagnosis of CVT is made in the ED, therapy should be instituted in the ED.

Treatment of Stroke

Admission is required for all pregnant patients diagnosed with a suspected CVA from any cause. Management begins with stabilization of the maternal vital signs, including blood pressure

control. The underlying cause must be determined to provide appropriate therapy. For the treatment of hemorrhagic strokes, all management, including surgical procedures, should proceed as if the patient were not pregnant.^{37,47}

In ischemic strokes, the etiology should be determined and appropriate treatment instituted based on the final cause. Anticoagulation with unfractionated heparin or low molecular weight heparin is reasonably safe in pregnancy, as neither molecule crosses the placenta. Anticoagulation should be based on the etiology of the stroke and should commence in the ED in consult with obstetrics and neurology.²⁹ Thrombolytic therapy may be indicated for a pregnant patient who presents within three hours of symptoms and is diagnosed with an ischemic stroke, but all studies evaluating thrombolytics for CVA excluded the pregnant patient, so very little data is available. Pregnancy is not an absolute contraindication to the use of t-PA, which is a Category C drug, meaning that the benefit of its use should outweigh the risks to the fetus.^{29,33,40,48} Newer, mechanical clot disruption devices or snares may be a more attractive option in the pregnant patient, but still are considered investigational procedures and are not readily available.^{29,33} From the ED perspective, making the diagnosis of a CVA should prompt the physician to consult the patient's obstetrician, neurology, and/or neurosurgery, depending on the etiology if the patient still is pregnant. As most CVAs occur in the first few postpartum weeks, the risk is only to the mother, and therefore proceeding with t-PA is based solely on maternal indications without worry about the fetus. The patient and/or her family should be informed of the potential risks and benefits and be included in the decision-making process.

Summary

- Any pregnant or newly delivered patient presenting with a headache or focal neurological deficits should undergo a thorough neurologic exam and be evaluated for hypertension and proteinuria.
- The risk of stroke is greatest in the puerperium.
- Rapid evaluation in patients suspected of having a stroke, including a head CT scan with abdominal shielding if pregnant, should be conducted.
- Pregnant patients who present with symptoms of stroke or cerebral venous thrombosis should be treated as those who aren't pregnant, including the use of t-PA if the patient presents within the three-hour window and the benefits to the mother outweigh the risk to the fetus.
- Lumbar puncture should be conducted if indicated.
- MRI should be obtained regardless of the pregnancy status of the patient, provided there is no alternative non-ionizing study to obtain the information, and the results will have an impact during the pregnancy and it would be deleterious to wait until the patient is postpartum.
- IV iodinated contrast for CT scan may be used, but may cause fetal hypothyroidism if used in the third trimester.
- MRI contrast should be given only if absolutely essential, as it does cross the placenta and is renally excreted by the fetus, although no studies have demonstrated adverse effects.

- If eclampsia is the final diagnosis, magnesium sulfate should be used to prevent further seizures.
- Anticoagulation with heparin or low molecular weight heparin should be used where indicated.
- Neurosurgical procedures should be conducted if indicated.
- The patient and her family should be kept apprised of the benefits and risks of all procedures, and it is recommended that informed consent be obtained before obtaining an MRI in the first trimester.

Headache

Initial Evaluation. The ED physician's role is to evaluate the patient for a life-threatening condition when a patient with a severe headache presents to the ED. A pregnant patient who presents with a chief complaint of headache should undergo a thorough history and physical exam with attention to prior history of headache, similarities between the current headache and previous headaches, results of any prior workup, and a physical exam with special attention to the blood pressure and neurologic exam. New headaches, changes in the character of the headache, neurologic findings, proteinuria, or other constitutional findings warrant further workup. Of particular concern, preeclampsia, eclampsia, and cerebral venous thrombosis all may present with headache as an initial symptom. A CT scan or MRI is necessary if headache character has changed or neurologic abnormalities are noted. A headache history suspicious for subarachnoid hemorrhage also should prompt a workup, including a CT with or without lumbar puncture (LP), depending on the CT results.⁴⁹ See discussion on stroke regarding the use of MRI in the pregnant patient. The contrast media used has been shown to cause adverse effects on animal fetuses at doses 2.5-7.5 times the human dose, but there are no human studies of safety of MRI contrast in pregnant females. It is recommended to defer contrast agents in pregnant patients unless the benefit is greater than the risk.^{38,39}

Usual Course of Migraines. Migraines affect 15-17% of the female population and often are linked to the sex hormones.^{50,51} In pregnant patients with migraines, there is a 60-70% improvement in the frequency of attacks, especially in the second and third trimesters, independent of migraine type,⁵¹ which often worsen again after delivery.⁴⁹ In one prospective study, 18% of patients presenting to a university based obstetrics and gynecology clinic in their first trimester suffered from migraines, with 83% having migraines without aura. Migraines improved substantially throughout the pregnancy (47% in the first trimester, 83% in the second, and 87% in the third), recurring in the first postpartum week in 34% and within the first month in 55%.⁵²

Management of Headaches in the ED. Once the ED physician has conducted an appropriate workup to discern the etiology of the headache, and comes to the conclusion that it is not life-threatening or related to a complication of pregnancy that might require additional treatment, such as preeclampsia or eclampsia, he or she should provide the least toxic acute therapy to control the symptoms. Attempts to avoid all triggers should be encouraged. In addition, preventive medications such as valproic acid should be avoided.⁴⁹ If the physician discovers that the patient is

pregnant in the ED and notes the use of valproic acid as a migraine prevention medication, the ED physician should notify the prescribing physician. If the patient is less than one trimester in gestation, she should be encouraged to discontinue the valproate if the sole use is for migraine prevention. As migraines generally improve greatly during pregnancy, this medication is likely unnecessary, and is known to cause serious fetal anomalies. In addition, a prescription should be written for folic acid 4 mg daily. If the patient is past the tenth week of gestation, the patient should be referred to obstetrics for a detailed evaluation of the fetus for birth defects. (*See previous discussion under seizures.*)

Acute measures for headache management may be as simple as a quiet environment and an ice pack. Non-pharmacological measures such as biofeedback and relaxation techniques may be effective, although not readily available in the ED.^{53,54} Acutely, acetaminophen with codeine (Tylenol #3), prochlorperazine (Compazine), metoclopramide (Reglan), trimethobenzamide (Tigan), or promethazine (Phenergan) are thought to be safe and effective. Parenteral narcotics such as morphine or meperidine (Demerol) may be necessary on rare occasions.^{49,51,55} Aspirin and non-steroidals may be used, but should be avoided in the third trimester because their use has been associated with preeclampsia, prolonged labor, persistent pulmonary hypertension in the neonate, premature narrowing of the ductus arteriosus, and an increased fetal and maternal risk of hemorrhage.⁵¹

Pseudotumor Cerebri

Although not the most accurate term to describe this condition, pseudotumor cerebri (PC) has been defined and studied since the late 1800s.⁵⁶ It is a condition of elevated intracranial pressure in the absence of intracranial space occupying lesions, abnormal ventricles, infections, or other CSF abnormalities. PC most often is associated with papilledema and headache, but lacks focal neurological deficits.⁵⁷ Another common but more recent term is idiopathic intracranial hypertension (IIH).⁵⁸ This disorder must be differentiated from CVT, which often presents similarly to IIH.⁴⁶ Pregnancy is a predisposing factor for both, and MRI or cerebral angiography should be performed to rule out CVT before assigning the diagnosis of IIH.^{59,60} Most patients with CVT present with an abrupt headache, which is considered severe and often is associated with papilledema, visual field and/or acuity loss, and diplopia.⁶¹ The patient with PC generally will have a more gradual onset of cephalgia, with concomitant papilledema, normal CSF studies with the exception of the opening pressure, and without focal neurologic deficits.⁵⁷ A small series of patients studied revealed that the pregnant patient with pseudotumor has an elevated cardiac output when compared to a non-affected pregnant patient.⁵⁷

The ED physician's role is to evaluate the patient for a life-threatening condition when a patient with a severe headache presents to the ED. If PC is the final diagnosis, consultation with neurology and obstetrics will determine the best course of action for the individual patient. Treatment for PC often is undertaken using acetazolamide (Diamox) to decrease the intracranial pressure. This poses some risk to the fetus, as diuretics have been shown to decrease amniotic fluid levels. Response to acetazo-

lamide with or without a beta-blocker was not shown to decrease the cardiac output below the mean expected.⁵⁷

Peripheral Neuropathies

Carpal Tunnel Syndrome (CTS). CTS, characterized by paresthesias in the median nerve distribution, is more common in females and may be hereditary. It is postulated that the reason for the nocturnal increase in symptoms is a result of blood volume redistribution from the legs while in the recumbent position. This is exacerbated by the pregnant state, especially the third trimester when blood volume is greatest. Symptoms often resolve after childbirth. When patients present to the ED with CTS, reassurance and the use of wrist splints may help alleviate the symptoms. Analgesics may be necessary initially, and their use should be based on the current age of the fetus. Occasionally surgery is necessary.⁶²

Meralgia Paresthetica. This mononeuropathy involving the lateral femoral cutaneous nerve (LFCN) results in paresthesias and dysesthesias in the anterior lateral middle third of the thigh. Occasionally symptoms may extend into the lateral calf. The LFCN is primarily a sensory nerve with variable nerve root origins in the upper lumbar spine. It most often passes medial and inferior to the anterior superior iliac spine and as such is exposed to compressive forces as the gravid uterus enlarges.^{63,64} This mononeuropathy occurs more frequently in those who suffer from CTS.⁶⁵ In pregnancy, conservative therapy often is all that is necessary because resolution after delivery is the norm. The diagnosis can be confirmed by injecting local anesthesia at the site where the nerve exits the pelvis, and occasionally surgical decompression or resection of the nerve is necessary in patients whose symptoms do not resolve within a few weeks postpartum.^{63,64} Presented with this patient in the ED, the physician can often make the diagnosis, provide reassurance and analgesia, and refer the patient to her obstetrician for further treatment.

Bell's Palsy. A peripheral 7th nerve disorder of uncertain etiology, the majority of cases that occur in pregnancy do so in the third trimester.^{66,67} Pregnant women are three times more likely than their non-pregnant cohort to develop Bell's palsy.⁶⁸ Of interest, gestational hypertension or preeclampsia was present or developed in 22.2% of cases of Bell's palsy, which is 3-5 times the rate for pregnancy in general.^{66,67} If complete facial paralysis is present, the prognosis for total recovery is significantly less in the pregnant patient than in the general population.⁶⁹ Neuroimaging is not necessary.⁶⁶ The Cochrane Database recently reviewed (May 2004) the use of acyclovir (Zovirax) or valacyclovir (Valtrex) for Bell's palsy and concluded that, although probably safe in pregnancy, more data are needed from large randomized studies to show definite benefit.⁷⁰ The practice parameter published in 2001 by the American Academy of Neurology regarding Bell's palsy gives acyclovir a safe but possibly effective recommendation for the general population. Regarding steroids, the rating was safe and probably effective, again for the general population. Because of the lack of randomized clinical trials, the natural course of the disease to improve to complete recovery in approximately 80% of those afflicted (albeit some-

what less in the pregnant patient) no recommendations are made by these two review bodies regarding steroids, acyclovir, or the combination of the two.⁷¹

In a Japanese study published in 2003, a retrospective comparison of prednisolone (Delta-Cortef) (1 mg/kg/day for 4 days then decreased over the following two weeks) with or without acyclovir (2000 mg/day for 7 days) concluded that the overall rate of improvement in patients treated with acyclovir and prednisolone was significantly better than those treated with just prednisolone, and complete recovery was 100% in the population that received therapy within 3 days of symptom onset. Therapy begun 4 days or later in the course of the disease showed no benefit to adding acyclovir to the prednisolone. No placebo was used for comparison. However, because this study was conducted on the general population with Bell's palsy, not the pregnant population, no recommendations can be made regarding this subset of patients with Bell's palsy.⁷²

The pregnant patient with Bell's palsy should receive artificial tears eye drops for daytime use and artificial tears ointment with patching for nighttime use. Serious consideration should be given to the use of prednisone and acyclovir, especially in the patient with complete facial hemiparalysis who presents within 3 days of symptom onset, in consultation with the patient's obstetrician. Acyclovir is pregnancy category B, meaning it is presumed safe based on animal studies, while prednisone is pregnancy category C, meaning there are no human studies, and animal studies reveal an adverse profile.⁴⁸

Movement Disorders

Restless Legs Syndrome (RLS). RLS is a disorder with an uncertain pathogenesis that is characterized by deep paresthesias and dysesthesias, primarily in the calves. The sensations are worse at rest and resolve with movement, often causing a marked disturbance of sleep. Conditions other than pregnancy associated with this disorder include iron, folic acid, or B-12 deficiency; uremia; diabetes mellitus; rheumatoid arthritis; and a multitude of other conditions. Twenty-five to 50% of patients have idiopathic disease. Diagnosis usually is made by conducting a thorough history, and treatment often revolves around correcting the underlying cause. Up to 19% of pregnancies are affected by RLS.⁷³⁻⁷⁷

If the patient has no obvious vitamin deficiency, then treatment may include levodopa (Dopar, Larodopa), bromocriptine mesylate (Parlodel), narcotic analgesics, benzodiazepines, carbamazepine, or clonidine (Catapres).^{73,74} Phone consultation with the patient's obstetrician prior to prescription of any of these medications is in order, as the disorder usually subsides within a few weeks postpartum.⁷⁵⁻⁷⁸ Carbamazepine has been associated with congenital anomalies and should not be used in the first trimester.^{2,14}

Chorea Gravidarum. Chorea gravidarum has been described since the mid 1600s⁷⁹ and is a rare choreiform movement disorder that occurs in pregnancy. The estimated incidence is 1:139,000 pregnancies.⁸⁰ Now that cardiac evaluation is more sophisticated in the evaluation of patients with rheumatic fever, it is believed that most cases of what was thought to be chorea gravidarum actually are associated with a prior history of rheu-

matic fever, and may be as a result of hormonal effects on an already damaged basal ganglia. Occasional cases have been associated with lupus, antiphospholipid antibodies, syphilis and encephalitis.⁸¹ Dopamine receptor blockers may be used to control the symptoms when severe, again in consultation with the patient's obstetrician.⁸²

Multiple Sclerosis (MS)

MS is an autoimmune disease thought to be mediated by T-lymphocytes, with an as yet undefined pathogenesis. Numerous studies have been conducted on the effect of pregnancy on MS and relapses, with variable results. Compared to the pre-pregnancy year, MS patients have fewer relapses while pregnant, but experience an increased rate within the first three post-partum months.⁸³⁻⁸⁶ Despite an increased risk for the three months post-partum, 72% of women with MS did not experience a relapse during this time frame.⁸⁴ Other than an increased risk of maternal anemia, MS has no untoward effects on the pregnancy itself.⁸⁶ Women with MS are twice as likely to be re-hospitalized in the first three post-partum months when compared to their non-MS counterparts.⁸⁶

Infants born to women with MS were significantly more likely to experience meconium aspiration, but this did not correlate to prolonged complications. They are not more likely to have malformations.⁸⁶ Female, but not male, offspring have a 50-fold increase of developing MS when compared to the general population. This correlates to a 5% risk of developing the disease.⁸³

Treatment is based on symptoms and ED management should proceed similar to the non-pregnant patient. The effects of treatment modalities including interferon injections and high dose steroids for MS relapses have not been studied in infants exposed in-utero, and therefore no recommendations can be provided regarding these therapies.⁸⁶

Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disorder in which 85% of patients have antibodies to the acetylcholine receptors, causing disordered neuromuscular transmission and weakness of various muscle groups.⁸⁷ A 2:1 female to male ratio is noted, and it often affects women during their reproductive years.⁸⁸ Pregnancy has a variable effect on the course of this disease, even varying from pregnancy to pregnancy in the same patient. Fifty-nine percent of patients in one study had no change in their disease, while in 19% the disease worsened, and in 22% the disease improved.⁸⁹ Another reports a more even distribution of one-third each for improved, worsened, and no change. Postpartum exacerbations often are sudden and severe, resulting in maternal death. Maternal mortality has been reported at 40/1,000 live births.⁸⁸ In a 33-year retrospective study utilizing the Medical Birth Registry of Norway, Hoff et al reports on 127 births to mothers with MG. Women with MG have a higher rate of delivery complications, especially preterm membrane rupture, and a cesarean section rate twice that of the general pregnant population, with the majority being elective.⁹⁰

The mainstay of therapy is anticholinesterase medications, with pyridostigmine (Mestinon, Regonal) being the most common. Of importance, an overdose of these medications can cause an

increase in the weakness the patient experiences, along with respiratory failure requiring intubation, and occasionally results in death. Changes in intestinal absorption and renal excretion during pregnancy may alter blood levels and therefore therapeutic effects. Often high dose corticosteroids are used in the initial management of the patient, and antimetabolites such as azathioprine, gamma globulins, plasmapheresis, and thymectomy may be necessary.⁸⁸

Various studies report a 4-20% incidence of symptomatic neonatal myasthenia gravis (NMG) in infants born to mothers with MG.⁸⁹⁻⁹¹ This is due to the transfer of maternal antibodies to the acetylcholine receptor to the fetus. Symptoms may range from transient hypotonia, weak suckling, or a feeble cry to respiratory failure, and usually begin within hours of delivery and last for 2-3 weeks or more.^{88,92} Although many newborns test positive for the antibody to the acetylcholine receptor, the occurrence of NMG and maternal disease severity do not correlate.⁸⁹ It has been shown that mothers who transmit NMG to their infants have a higher ratio of antibody to fetal vs. adult acetylcholine receptors throughout their pregnancy, and this may have predictive value in determining which infants will develop the transient disease in the newborn period.⁹³ If these infants present to the ED due to failure to eat, apnea, or hypotonia, they should be treated with standard anticholinesterase medications.

MG is known for its multitude of drug/disease interactions. Amide anesthetics are safer than ester anesthetics due to metabolism of the latter by plasma cholinesterase.⁸⁸ Of note, magnesium sulfate is contraindicated in this patient population. Other medications that have been shown to be problematic include narcotics, tranquilizers, barbiturates, lithium, certain antibiotics, beta-blockers, and some inhalation anesthetics.^{88,94} These agents have been reported specifically, but caution should be used with any member of the same drug class, and before prescribing medication for the patient with MG, the ED physician should consult a reference. An extensive list of drugs that should be used with caution in the patient with MG is listed on page 1425 of the sixth edition of the *Emergency Medicine Comprehensive Study Guide* by Tintinalli et al.⁹⁵

Brain Tumors

Although not specifically a disease of pregnancy, tumors involving the nervous system may first become apparent during the pregnancy period. The incidence is the same as for the non-pregnant patient, with the exception of metastatic choriocarcinomas, melanoma, and breast carcinoma, which have an increased rate of occurrence. The incidence of choriocarcinoma is 1:50,000 after full-term pregnancy, but 1:30 following a molar pregnancy. Meningiomas and pituitary adenomas have increased growth during the pregnant period due to hormonal effects.^{96,97} Patients presenting to the ED with headache or what they assume to be protracted nausea and vomiting due to morning sickness should undergo a thorough neurologic exam to rule out focal neurologic deficits that may indicate a space occupying lesion. If there is any suspicion that a more serious condition exists, the ED physician should complete a further diagnostic evaluation, including a CT scan if indicated.

Summary

In summary, neurologic complications of pregnancy may range from life-threatening to merely a nuisance to be endured by the gravid patient. Bearing in mind that there are two patients when dealing with the myriad of neurologic disorders possible, and keeping rare but important items in the differential when evaluating the pregnant patient with such common complaints as headache when they present to the ED, is essential to thorough EM care. A thorough neurological examination should be included in the evaluation of every pregnant patient that presents with a complaint of headache or nausea and vomiting. Early consultation with the patient's obstetrician is often necessary for definitive care, and in addition, the ED physician should not hesitate to consult neurology early to assist in the management of these neurologic disorders.

References

1. Rochester JA, Kirchner JT. Epilepsy in pregnancy. *Am Fam Physician* 1997;56:1631-1636.
2. Foldvary N. Treatment issues for women with epilepsy. *Neurol Clin* 2001; 19:409-425.
3. Swartjes JM, van Geijn HP. Pregnancy and epilepsy. *Eur J Obstet Gynecol Reprod Biol* 1998;79:3-11.
4. [No authors listed.] Practice parameter: Management issues for women with epilepsy (summary statement): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 1998;51:944-948.
5. Consensus statements: Medical management of epilepsy. *Neurology* 1998; 51(Suppl 4):S39-S43.
6. Henshaw SK. Unintended pregnancy in the United States. *Family Plann Perspect* 1998;30:24-29.
7. Morrell M. Guidelines for the care of women with epilepsy. *Neurology* 1998;51:S21-27.
8. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. *Drugs* 1999;57:535-544.
9. Delgado-Escueta AV, Janz D. Consensus guidelines: Preconception counseling, management, and care of the pregnant women with epilepsy. *Neurology* 1992; 42(4 Suppl 5):149-160.
10. Yerby MS. Pregnancy, teratogenesis, and epilepsy: Reproduction and effects of pregnancy on epilepsy. *Neurol Clin* 1994;12:749-771.
11. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: Report of a collaborative study group in Japan. *Epilepsia* 1980;21:663-680.
12. Malone FD, D'Alton ME. Drugs in pregnancy: Anticonvulsants. *Semin Perinatol* 1997;21:114-123.
13. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. *Neurology* 2003;61:S35-42.
14. Holmes LB, Harvey EA, Coull, BA, et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med* 2001;355:1132-1138.
15. Pennell PB. The importance of monotherapy in pregnancy. *Neurology* 2003;60:S31-38.
16. Pschirrer ER. Seizure disorders in pregnancy. *Obstet Gynecol Clin North Am* 2004;31:373-384.
17. Barrett C, Richens A. Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop. *Epilepsy Research* 2003;52:147-187.
18. Montouris G. Gabapentin exposure in human pregnancy: Results from the

- Gabapentin Pregnancy Registry. *Epilepsy Behav* 2003;4:310-317.
19. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: A meta-analysis. *Drug Saf* 2004;27:197-202.
 20. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. *Neurology* 2003;60:575-579.
 21. Pschirrer ER, Monga M. Seizure disorders in pregnancy. *Obstet Gynecol Clin North Am* 2001;28:601-611.
 22. Yerby MS. Management issues for women with epilepsy: Neural tube defects and folic acid supplementation. *Neurology* 2003;61:S23-26.
 23. Reynolds EH. Anticonvulsants, folic acid, and epilepsy. *Lancet* 1973;1:1376-1378.
 24. Makki MA, Perruca E, Richens A. Stimulation of drug metabolism by folate replacement in folate-deficient epileptic patients. *Br J Clin Pharmacol* 1979;1:304P-305P.
 25. Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folic acid interaction. *Ann Pharmacother* 1995;29:726-735.
 26. Chouluka S, Grabowski E, Holmes LB. Is antenatal vitamin K prophylaxis needed for pregnant women taking anticonvulsants? *Am J Obstet Gynecol* 2004;190:882-883.
 27. Desmond MM, Schwanecke RP, Wilson GS, et al. Maternal barbiturate utilization and neonatal withdrawal symptomatology. *J Pediatr* 1972;80:190-197.
 28. Richmond JR, Krishnamoorthy P, Andermann E, et al. Epilepsy and pregnancy: An obstetric perspective. *Am J Obstet Gynecol* 2004;190:371-379.
 29. Waddy S, Stern BJ. Cerebrovascular disease in pregnancy. *Current Science* 2003;5:241-249.
 30. Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. *N Engl J Med* 1996;335:768-774.
 31. Jaigobin C, Silver FL. Stroke and pregnancy. *Stroke* 2000;31:2948-2951.
 32. Sharshar T, Lamy C, Mas JL. Incidence and causes of strokes associated with pregnancy and the puerperium. A study in public hospitals of Ile de France. *Stroke* 1995;26:930-936.
 33. Shehata, JA, Okosun H. Neurological disorders in pregnancy. *Curr Opin Obstet Gynecol* 2004;16:117-122.
 34. Jeng JS, Tang SC, Up PK. Stroke in women of reproductive age: Comparison between stroke related and unrelated to pregnancy. *J Neurol Sci* 2004;221:25-29.
 35. Coppage KH, Hinton AC, Moldenhauer J, et al. Maternal and perinatal outcome in women with a history of stroke. *Am J Obstet Gynecol* 2004;190:1331-1334.
 36. Donaldson JO, Lee NS. Arterial and venous stroke associated with pregnancy. *Neurol Clin* 1994;12:583-589.
 37. Mas JL, Lamy C. Stroke in pregnancy and the puerperium. *J Neurol* 1998;245:305-313.
 38. Nagayama M, Wantanabe Y, Okumura A, et al. Fast MR imaging in obstetrics. *Radiographics* 2002;22:563-580.
 39. Chung SM. Safety issues in magnetic resonance imaging. *J Neuroophthalmol* 2002;22:35-39.
 40. Turan TN, Stern BJ. Stroke in pregnancy. In: Pennell PB, ed. *Neurology Illnesses and Pregnancy*. *Neurol Clin* 2004;22:821-840.
 41. Sherlock FG, Cruess JV 3rd. MR safety and the American College of Radiology White Paper. *AJR* 2002;178:1349-1352.
 42. Harrison BP, Crystal CS. Imaging modalities in obstetrics and gynecology. *Emerg Med Clin North Am* 2003;21:711-735.
 43. Kok RD, de Vries MM, Heerschap A, et al. Absence of harmful effects of magnetic resonance exposure at 1.5R in utero during the third trimester of pregnancy: A follow-up study. *Magn Reson Imaging* 2004;22:851-854.
 44. Estroff JA. Prenatal diagnosis and imaging of genetic syndromes. *Semin Roentgenol* 2004;39:323-335.
 45. Garel C, Brisse H, Sebag G, et al. Magnetic resonance imaging of the fetus. *Pediatr Radiol* 1998;28:201-211.
 46. Ameri A, Bousser MG. Cerebral venous thrombosis. *Neurol Clin* 1992;10:87-111.
 47. Leys D, Lamy C, Lucas C, et al. Arterial ischemic strokes associated with pregnancy and puerperium. *Acta Neurol Belg* 1997;97:5-16.
 48. Silbertstein SD. Headaches in pregnancy. In: Pennell PB, ed. *Neurology Illnesses and Pregnancy*. *Neurol Clin* 2004;22:727-756.
 49. Marcus D. Focus on Primary Care. Diagnosis and management of headache in women. *Obstet Gynecol Surv* 1999;54:395-402.
 50. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence: A review of population-based studies. *Neurology* 1994;44(6 suppl 4):S17-23.
 51. Aube M. Migraine in pregnancy. *Neurology* 1999;53(Suppl 1):S26-S28.
 52. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: A prospective study. *Cephalgia* 2003;23:197-205.
 53. Warner G. Relaxation therapy in migraine and chronic tension headache. *Med J Aust* 1975;1:298-301.
 54. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. *Headache* 1981;21:105-109.
 55. Gilmore J, Pennell PB, Stern BJ. Medication use during pregnancy for neurologic conditions. *Neurol Clin* 1998;16:189-206.
 56. Bandyopadhyay S. Pseudotumor cerebri. *Arch Neurol* 2001;58:1699-1701.
 57. Gavrilu D, Carr D, Brateng D, et al. 366 hemodynamics of pseudotumor cerebri in pregnancy. *Am J Obstet Gynecol* 2001;185 Suppl 6:S181.
 58. Piette JC, Wechsler B, Vidailhet M. Idiopathic intracranial hypertension: Don't forget cerebral venous thrombosis. *Am J Med* 1994;97:200.
 59. Bousser JG, Barnett HJM. Cerebral venous thrombosis. In: Barnett HJM, Mohr JP, Stein BM, et al, eds. *Stroke: Pathophysiology, Diagnosis and Management*. 2nd ed. Edinburgh: Churchill Livingstone; 1992:517-537.
 60. Tehindranarivelo AD, Bousser MG. Idiopathic intracranial hypertension and cerebral dural sinus thrombosis. *Am J Med* 1994;97:200-201.
 61. Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. *Arch Neurol* 1995; 52:880-885.
 62. Radecki P. Personal factors and blood volume movement in causation of median neuropathy at the carpal tunnel. *Am J Phys Med Rehabil* 1996;75:235-238.
 63. Ivins GK. Meralgia paresthetica, the elusive diagnosis: Clinical experience with 14 adult patients. *Ann Surg* 2000;232:281-286.
 64. Rhodes P. Meralgia paresthetica in pregnancy. *Lancet* 1957;273:831.
 65. van Slobbe AM, Bohnen AM, Bernsen RM, et al. Incidence rates and determinants in meralgia paresthetica in general practice. *J Neurol* 2004;251:294-297.
 66. Shapiro JL, Yudin MH, Ray JG. Bell's palsy and tinnitus during pregnancy: Predictors of pre-eclampsia? Three cases and a detailed review of the literature. *Acta Otolaryngol* 1999;119:647-651.
 67. Shmorgun D, Chan WS, Ray JG. Association between Bell's palsy in pregnancy and pre-eclampsia. *Q J Med* 2002;95:359-362.
 68. Hilsinger Jr RL, Adour KK, Doty HE. Idiopathic facial paralysis, pregnancy, and the menstrual cycle. *Ann Otol Rhinol Laryngol* 1975;84:433-442.
 69. Gillman GS, Schaitkin BM, May M, et al. Bell's palsy in pregnancy: A study of recovery outcomes. *Otolaryngol Head Neck Surg* 2002;126:26-30.

70. Allen D, Dunn L. Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). *Cochrane Database Syst Rev* 2004;(3):CD001869.
71. Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001;56:830-836.
72. Hato N, Matsumoto S, Kisaki H, et al. Efficacy of early treatment of Bell's palsy with oral acyclovir and prednisolone. *Otology & Neurotology* 2003;24:948-951.
73. Tan EK, Ondo W. Restless legs syndrome: Clinical features and treatment. *Am J Med Sciences* 2000;319:397-403.
74. O'Keeffe ST. Restless legs syndrome: A review. *Arch Intern Med* 1996;156:243-248.
75. Ondo W, Jankovic J. Restless legs syndrome. In: Appel SH, ed. *Current Neurology*. Amsterdam: IOS Press; 1997:207-235.
76. Goodman JDS, Brodie C, Ayida GA. Restless legs syndrome in pregnancy. *BMJ* 1988;297:1101-1102.
77. Botez MI, Lambert B. Folate deficiency and restless legs syndrome in pregnancy. *N Engl J Med* 1997;297:670.
78. Thorpy M, Ehrenberg BL, Hening WA, et al. Restless legs syndrome: Detection and management in primary care. *Am Fam Physician* 2000;62:108-114.
79. Cardoso F. Chorea gravidarum. *Arch Neurol* 2002;59:868-870.
80. Zegart KN, Schwarz RH. Chorea gravidarum. *Obstet Gynecol* 1968;32:24-27.
81. Cardoso F, Vargas AP, Cunningham MCQ, et al. Chorea gravidarum: New lessons from an old disease. *Neurology* 1999;52 Supl 2:A121.
82. Golbe LI. Pregnancy and movement disorders. *Neurol Clin* 1994;12:497-508.
83. Damek DM, Shuster EA. Pregnancy and multiple sclerosis. *Mayo Clin Proc* 1997;72:977-989.
84. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMIS study): Clinical predictors of post-partum relapse. *Brain* 2004;127(Pt6):1353-1360.
85. Salemi G, Callari G, Gammino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: A cohort study. *Acta Neurol Scand* 2004;110:23-26.
86. Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. *Am J Obstet Gynecol* 2002;186:446-452.
87. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. *J Neurol Neurosurg Psychiatry* 1985;48:1246-1252.
88. Plauche WC. Myasthenia gravis in mothers and their newborns. *Clin Obstet Gynecol* 1991;34:82-99.
89. Batocchi AP, Majolini L, Evoli A, et al. Course and treatment of myasthenia gravis during pregnancy. *Neurology* 1999;52:447-452.
90. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: Consequences for pregnancy, delivery, and the newborn. *Neurology* 2003;61:1362-1366.
91. Papazian O. Transient neonatal myasthenia gravis. *J Child Neurol* 1992;7:135-141.
92. Vernet-der Garabedian B, Lacokova M, Eymard B, et al. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. *J Clin Invest* 1994;94:555-559.
93. Gardnerova M, Eymard B, Morel E, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. *Neurology* 1997;48:50-54.
94. Wittbrodt ET. Drugs and myasthenia gravis. An update. *Arch Intern Med* 1997;157:399-408.
95. Sloan EP. Chronic Neurologic Disorders. Table: Drugs that should be used with caution in patients with Myasthenia Gravis. In: Tintinalli JE, Kelen GD, Stapczynski JS, eds. *Emergency Medicine: A Comprehensive Study Guide*. New York: McGraw-Hill; 2004:1425.
96. Ortiz AO, Kittner ST, Maulik D, et al. Neuroimaging of pregnancy-related maternal neurologic complications. *Journal of Women's Imaging* 2001;3:14-28.
97. Roelvink NC, Kamphorst W, van Alphen HA, et al. Pregnancy-related primary brain and spinal tumors. *Arch Neurol* 1987;44:209-215.

Physician CME Questions

21. The usual course of migraine headaches in pregnancy is:
- most patients have a decrease in frequency during pregnancy, returning to baseline in the first few weeks postpartum.
 - decreased frequency in first trimester, return to baseline during third trimester.
 - increased frequency during first trimester, decreasing for remainder of pregnancy.
 - no change in frequency.
 - no trends have been noted.
22. Regarding strokes in pregnancy, which of the following is the period of greatest risk?
- First trimester
 - Second trimester
 - Third trimester
 - Puerperium
 - The risk is similar throughout pregnancy.
23. Intracranial hypertension:
- always is associated with high blood pressure.
 - often presents with a headache and photophobia.
 - is defined as elevated intracranial pressure without focal neurologic deficits, often with papilledema.
 - most commonly causes seizures as an initial presentation.
24. Which of the following statements is true of Bell's palsy?
- It occurs at a rate less than that of the general population during pregnancy, but fewer patients affected undergo complete resolution of the facial palsy.
 - All patients should be prescribed steroids and acyclovir.
 - It is an eighth nerve palsy, afflicting hearing and balance.
 - Although 80% of the general population with Bell's palsy experience complete recovery, the prognosis is worse for pregnant patients with the condition.
25. Which drug routinely used to treat the eclamptic patient suffering from a seizure is absolutely contraindicated in the patient with myasthenia gravis?
- Phenobarbital

- B. Phenytoin
 - C. Magnesium sulfate
 - D. Diazepam
 - E. Midazolam
26. Anti-epileptic drugs such as valproic acid, phenytoin, carbamazepine:
- A. cause a 10-fold increase in congenital anomalies in fetuses exposed during the first 10 weeks of gestation.
 - B. should be discontinued if pregnancy in the first trimester is diagnosed in the ED
 - C. rarely interfere with the metabolism of birth control pills.
 - D. should be monitored using free drug levels.
 - E. often cause anencephaly.
27. Regarding diagnostic testing for suspected neurologic disorders (CT, MRI, lumbar puncture), which of the following is true?
- A. Tests should be delayed until the post-partum period in most cases.
 - B. Tests should proceed as if the patient were not pregnant, providing the conditions being evaluated will result in therapeutic changes for the mother during the pregnancy.
 - C. Tests should never utilize iodinated contrast agents due to fetal hypothyroidism that may occur with their administration in the third trimester.
 - D. MRI, in particular, is contraindicated during the third trimester.
28. Regarding seizures in pregnancy, which of the following is true?
- A. There is a 10-fold increase in maternal mortality in patients who suffer a seizure while pregnant.
 - B. Seizures often result from maternal non-compliance with medications.

- C. Seizures may cause abruption of the placenta, premature rupture of membranes, and fetal demise.
 - D. Initial management includes benzodiazepines.
 - E. All of the above
29. Neonatal withdrawal symptoms due to maternal use of phenobarbital never is observed beyond one week after birth.
- A. True
 - B. False
30. Both multiple sclerosis and migraine headaches experience a rate increase postpartum compared with during pregnancy.
- A. True
 - B. False

In Future Issues:

Common Dermatology Presentations

CME Answer Key

- | | |
|-------|-------|
| 21. A | 26. D |
| 22. D | 27. B |
| 23. C | 28. E |
| 24. D | 29. B |
| 25. C | 30. A |

Emergency Medicine Reports

CME Objectives

To help physicians:

- quickly recognize or increase index of suspicion for specific conditions;
- understand the epidemiology, etiology, pathophysiology, and clinical features of the entity discussed;
- apply state-of-the-art diagnostic and therapeutic techniques (including the implications of pharmaceutical therapy discussed) to patients with the particular medical problems discussed;
- understand the differential diagnosis of the entity discussed;
- understand both likely and rare complications that may occur.

CME Instructions

Physicians participate in this continuing medical education program by reading the article, using the provided references for further research, and studying the questions at the end of the article. Participants should select what they believe to be the correct answers, then refer to the list of correct answers to evaluate their knowledge. To clarify confusion surrounding any questions answered incorrectly, please consult the source material. *After completing this activity, you must complete the evaluation form that will be provided at the end of the semester and return it in the reply envelope provided to receive a certificate of completion.* When your evaluation is received, a certificate will be mailed to you.

Patient Education for Women on Antiepileptic Drugs for Any Reason

- You have been diagnosed with pregnancy, and are noted to be on one of several anti-epileptic drugs.
- If these medications are being taken for the management of epilepsy you should consult the health care provider managing your seizures.
- If these medications are being taken for migraine prophylaxis or as a mood stabilizer, consult the health care provider managing these conditions.
- Anti-epileptic drugs have been associated with an increased risk of birth defects in infants born to mothers who take them. These abnormalities occur during the first 10 weeks of your pregnancy.
- This risk is 2-3 times that of the population not taking these medications. However, more than 90% of pregnancies that occur while the mother is taking one of these medications produce healthy newborns.
- DO NOT stop taking these medications without consulting your physician, particularly if you are using them for seizure control. A seizure is also harmful to you and your baby. It may cause chemical imbalances in the blood, and trauma-related injuries to you or the baby may be fatal to one or both of you.
- If you are not already doing so, DO begin taking folic acid. A prescription for 4 mg/day is being provided until you can visit the obstetrician.
- DO arrange obstetrical follow up and follow their recommendations regarding the use of medications.
- DO adjust your lifestyle to avoid known triggers for your seizures. This includes getting enough rest; avoiding illicit drugs, alcohol, cigarettes, and prolonged exposure to flashing lights from any source (i.e., video games, computer screens, strobe lights).

Emergency Medicine Reports®

For a complete title index,
please see page 20.

Volume 25

SUPPLEMENT

2004 Subject Index: Volume 25, Numbers 1-26

Entries are organized alphabetically by subject matter and key words, with entries followed by the issue number and page number (e.g., issue number 2, page 20 would be listed as 2:20). Tables are indicated by a lowercase *t*, figures by a lowercase *f*. Supplements are indicated by an uppercase *S* or their report number. Trauma Reports is indicated by Trauma and then the issue number and page number.

<p>A</p> <p>AAA. See Abdominal aortic aneurysm</p> <p>AAEM. See American Academy of Emergency Medicine</p> <p>AAFP. See American Academy of Family Physicians</p> <p>AAOHN. See American Academy of Otolaryngology and Head and Neck Surgery</p> <p>AAP. See American Academy of Pediatrics</p> <p>Abciximab (ReoPro) combined with retevase, 8:97 for ST-elevation MI, 7:85, 8:92t, 93t, 95-96, 96t, 97</p> <p>Abdominal aortic aneurysm, 23:285</p> <p>Abdominal pain acute, 22:273-278, 275t, 23:281-289, 283t non-abdominal causes, 22:278, 23:286 unusual causes of, 23:288-289</p> <p>Abdominal surgery, 23:286</p> <p>Abortion, spontaneous, 23:288</p> <p>Abrasions, corneal, 18:221-222</p> <p>ABRS. See Acute bacterial rhinosinusitis</p> <p>Abruptio placentae, 23:288</p> <p>Abscess pancreas transplant, 2:23 parapharyngeal, 21:268 peritonsillar, 21:264-266 retropharyngeal, 21:268-269 stroke mimic, 5:60</p> <p>Abuse and neglect, elder, 23:286</p> <p>ACEP. See American College of Emergency Physicians</p> <p>Acetaminophen for acute bacterial rhinosinusitis, 9:103t, 10:119t for influenza, 15:186 for upper respiratory tract infections and sinusitis, 9:108t, 10:118t</p> <p>Acetic acid for otitis externa, 20:246 for paronychia, 13:156</p> <p>Acetylsalicylic acid. See Aspirin</p> <p>ACIP. See Advisory Committee on Immunization</p>	<p>Practices</p> <p>ACTH. See Adrenocorticotropic hormone</p> <p>Acute abdominal pain, 22:273 causes of, 22:275t, 23:283t in immunocompromised patients, 23:286-287 in older patients, 23:281-286 in pediatric patients, 22:274-278 in pregnant patients, 23:287-288</p> <p>Acute adrenal crisis, 23:288-289</p> <p>Acute bacterial rhinosinusitis AAOHN guidelines, 10:115 antibiotic selection for, 9:106-110 antibiotic therapy for, 9:101-110, 103t, 10:113-121 antimicrobial treatment issues, 9:104 definition of, 9:102-103, 105-106 diagnosis of, 9:103-104, 10:117 differential diagnosis of, 9:105-106, 105t, 10:117 drug resistance in, 9:104-105 epidemiological patterns, 9:104-105 microbiology of, 9:107 patient evaluation in, 10:117-119 referral triggers, 9:105-106, 106t short-course therapy for, 10:113-114 signs and symptoms associated with, 9:105, 105t treatment guidelines, 9:109t, 110t, 10:120t, 121t Year 2004 ATBS Clinical Consensus Panel Report® and Treatment Recommendations, 9:101-110, 10:113-121</p> <p>Acute coronary syndrome, 8:89</p> <p>Acute fatty liver of pregnancy, 24:300</p> <p>Acute gastroenteritis, 22:277</p> <p>Acute infectious epiglottitis, 21:267</p> <p>Acute intermittent porphyria, 23:289</p> <p>Acute myocardial infarction, 7:81 fibrinolytic therapy for, 8:89 golden hour in, 7:83 reperfusion therapy for, 7:81-88</p> <p>Acute rheumatic fever, 21:264</p> <p>Acylovir (Zovirax) for Bell's palsy, 21:262-263 for pharyngitis, 21:264t</p>	<p>Adalat. See Nifedipine</p> <p>Adenovirus, 21:264t</p> <p>Adhesives, 17:212-214</p> <p>Adrenal crisis, 23:288-289</p> <p>Adrenal insufficiency, 23:289</p> <p>Adrenocorticotropic hormone stimulation test, 23:289</p> <p>Advanced trauma life support, 17:205</p> <p>ADVANCE-MI trial, 8:97</p> <p>Adverse events potential, S04180:3, 3t preventable, S04180:3, 3t</p> <p>Advil. See Ibuprofen</p> <p>Advisory Committee on Immunization Practices (ACIP), 26:328</p> <p>Aerobacter aeruginosa, 21:270</p> <p>Aeromonas hydrophila in cellulitis, 13:153t, 154 risk factors for, 13:151t</p> <p>African-Americans facial wound repair in, 17:214 ischemic stroke in, 5:57 necrotizing fasciitis in, 14:169 pulmonary embolism in, 12:143 risk of stroke in, 5:62 stroke in, 5:64</p> <p>AGE. See Acute gastroenteritis</p> <p>Age and pediatric foreign body ingestion, 3:30 and stroke, 5:64</p> <p>Aggrastat (tirofiban), 7:85</p> <p>AIP. See Acute intermittent porphyria</p> <p>Air embolism acute, 4:53 in blast injuries, 4:42 precautions, 4:53 stroke mimic, 5:60 treatment of, 4:53</p> <p>Air Primary Angioplasty in Myocardial Infarction (AIR-PAMI) trial, 8:94</p> <p>Airway management</p>
---	---	--

<p>alternative techniques for, 17:203-204</p> <p>difficult, 17:203-204</p> <p>in esophageal foreign bodies, 3:35</p> <p>and facial trauma, 17:202-204, 203t</p> <p>Alaska, 25:318</p> <p>Alcohol consumption, 5:62</p> <p>Aldomet (methyldopa), 24:295, 298</p> <p>Allesse, 25:312t</p> <p>Allograft nephropathy, chronic, 2:18</p> <p>ALS. <i>See</i> Antilymphocyte serum</p> <p>Alteplase (t-PA)</p> <p>combined with PCI, 8:97</p> <p>for ST-elevation MI, 7:83, 8:96t</p> <p>Amantadine (Symmetrel)</p> <p>for influenza, 15:184, 185t, 26:324</p> <p>precautions and toxicity, 26:325t</p> <p>recommended daily dosage, 26:326t</p> <p>Ambulances, 1:8</p> <p>American Academy of Emergency Medicine (AAEM), 6:74</p> <p>American Academy of Family Physicians (AAFP)</p> <p>guidelines for antibiotic use in sinusitis, 10:119</p> <p>recommendations for otitis media, 20:249, 250t</p> <p>American Academy of Neurology, 21:262</p> <p>American Academy of Otolaryngology and Head and Neck Surgery (AAOHS), 10:115</p> <p>American Academy of Pediatrics (AAP)</p> <p>new recommendations for influenza vaccination, 26:328</p> <p>recommendations for otitis media, 20:249, 250t</p> <p>American Association of Poison Control Centers, 3:30</p> <p>American College of Cardiology/American Heart Association (ACC/AHA)</p> <p>recommendations for prehospital ECG transmission and fibrinolysis, 7:84-85</p> <p>recommended door-to-balloon time, 8:91</p> <p>recommended door-to-thrombolytic time, 7:83</p> <p>American College of Emergency Physicians (ACEP)</p> <p>policy and resource education for tPA in acute ischemic stroke, 6:74, 75t</p> <p>policy statement on thrombolytics for acute ischemic stroke, 6:74</p> <p>recommendations for emergency contraception, 25:311</p> <p>recommendations for procedural sedation, 17:209</p> <p>American College of Obstetricians and Gynecologists (ACOG)</p> <p>definition of pregnancy-induced hypertension, 24:294</p> <p>recommendations for emergency contraception, 25:311, 317</p> <p>American College of Physicians-American Society of Internal Medicine, 10:119</p> <p>American College of Radiology, 10:119</p> <p>American Stroke Association (ASA)</p> <p>guidelines for early management of ischemic stroke, 6:73</p> <p>recommendations for stroke units, 6:75</p>	<p>American Thoracic Society (ATS), 16:190</p> <p>AMI. <i>See</i> Acute myocardial infarction</p> <p>Aminoglycosides</p> <p>for community-acquired pneumonia, 16:193t, 194t</p> <p>for necrotizing fasciitis, 14:172t</p> <p>Amobarbital (Amytal), 24:302</p> <p>Amoxicillin (Amoxil)</p> <p>for acute bacterial rhinosinusitis, 9:109t, 110, 10:120t, 121</p> <p>for acute otitis media, 20:250t</p> <p>for community-acquired pneumonia, 16:192, 193t, 195t</p> <p>for human and mammalian bites, 14:167t</p> <p>for otitis media, 20:249</p> <p>for pharyngitis, 21:264t</p> <p>Amoxicillin/clavulanate (Augmentin)</p> <p>for acute bacterial rhinosinusitis, 9:104, 107, 109, 109t, 110, 110t, 10:115, 117, 120t, 121, 121t</p> <p>for acute otitis media, 20:249, 250t</p> <p>for cheek wound repair, 18:227</p> <p>for community-acquired pneumonia, 16:193t, 194t-195t</p> <p>for facial wound repair, 17:207</p> <p>for pediatric bite wounds, 19:239</p> <p>for septal hematoma, 18:227</p> <p>for sialadenitis, 20:256</p> <p>for traumatic TM perforation, 19:237</p> <p>Amphetamines, 5:62</p> <p>Ampicillin (Omnipen, Polycillin, Principen)</p> <p>for acute cholecystitis, 23:284</p> <p>for epiglottitis, 21:268</p> <p>for pharyngitis, 21:264t</p> <p>for volvulus, 22:275</p> <p>Ampicillin/sulbactam (Unasyn)</p> <p>for acute cholecystitis, 23:284</p> <p>for community-acquired pneumonia, 16:192, 193t, 195t</p> <p>for human and mammalian bites, 14:167t</p> <p>Anaerobes, 14:167t</p> <p>Analgesics</p> <p>for acute bacterial rhinosinusitis, 9:103t, 107, 10:119t</p> <p>for upper respiratory tract infections and sinusitis, 9:108t, 10:118t</p> <p>Anatomy</p> <p>ear, 20:245-246</p> <p>involved with esophageal foreign bodies, 3:29-30</p> <p>Anchoring, S04180:5t</p> <p>Anectine (succinylcholine), 24:302</p> <p>Anesthesia</p> <p>for facial wound repair, 17:208-209</p> <p>local, 17:209, 209t</p> <p>Aneurysm, abdominal aortic, 23:285</p> <p>Angina epiglottidea anterior, 21:267</p> <p>Angina, Ludwig's, 21:270</p> <p>Angiography</p> <p>CT, 6:72, 11:131, 132</p> <p>pulmonary, 11:132</p> <p>Angioplasty, 8:97</p> <p>Angiotensin receptor blockers, 5:62</p> <p>Angiotensin-converting enzyme inhibitors</p>	<p>for prevention of stroke, 5:62</p> <p>for ST-elevation MI, 8:92t</p> <p>Anistreplase, 7:83</p> <p>Anterior cerebral artery syndrome, 5:64</p> <p>Anterior choroidal artery syndrome, 5:65</p> <p>Antibiotic resistance, 16:191-192</p> <p>Antibiotic Selection for Community-Acquired Pneumonia Consensus Panel (ASCAP)</p> <p>antibiotic treatment guidelines, 16:190</p> <p>Year 2004 guidelines for management of community-acquired pneumonia, 16:194t-195t</p> <p>Antibiotic therapy</p> <p>for acute bacterial rhinosinusitis, 9:101-110, 103t, 109t, 110t, 10:113-121, 119t, 120t, 121t</p> <p>for acute otitis media, 20:249, 250t</p> <p>for cellulitis, 13:154</p> <p>for community-acquired pneumonia, 16:191-195, 192t, 193t, 194t-195t, 196</p> <p>for dog and cat bites, 14:166</p> <p>for erythrasma, 13:153</p> <p>for facial wound repair, 17:207</p> <p>for folliculitis, 13:152</p> <p>for frontal sinus fractures, 18:219</p> <p>for furunculosis with surrounding cellulitis or systemic signs, 13:152</p> <p>guidelines for, 16:190</p> <p>indications for, 9:107</p> <p>initial empiric therapy, 16:193t</p> <p>newer antibiotics, 16:191-195</p> <p>for otitis externa, 20:246-247</p> <p>pathogen-specific, 13:154</p> <p>regimens for GABHS pharyngitis, 21:263-264, 266t</p> <p>resistance, 16:191-195</p> <p>risk factors for pneumococcal resistance, 20:249, 249t</p> <p>selection of, 9:106-110</p> <p>short-course therapy, 10:113-114</p> <p>for sialadenitis, 20:256</p> <p>for upper respiratory tract infections and sinusitis, 9:108t, 10:118t</p> <p>Year 2004 ASCAP guidelines for management of community-acquired pneumonia, 16:194t-195t</p> <p>Anticholinergics, 9:103t, 10:119t</p> <p>Anticoagulation</p> <p>with inferior vena caval filters, 12:143</p> <p>warfarin therapy, 5:63-64, 12:140, 143</p> <p>Anticonvulsants</p> <p>dosage regimens, 24:298t</p> <p>for eclampsia, 24:302</p> <p>Anti-D immune globulin (RhoGam), 23:288</p> <p>Antihistamines, 9:108t, 10:118t</p> <p>Antihypertensives</p> <p>for ischemic stroke, 6:73</p> <p>for prevention of stroke, 5:62</p> <p>usage in pregnancy, 24:295-298, 297t, 300</p> <p>Antilipidemic agents, 5:62</p> <p>Antilymphocyte monoclonal antibody preparations, 2:16</p> <p>Antilymphocyte serum, 2:16</p> <p>Antimicrobial therapy</p>
--	---	---

for acute bacterial rhinosinusitis, 9:104
for human and mammalian bites, 14:167t
for necrotizing fasciitis, 14:172t
for otitis externa, 20:246-247, 248t
short-course therapy, 10:113-114
topical preparations, 20:248t

Antiplatelet agents
for prevention of stroke, 5:62-63, 6:74
for ST-elevation MI, 8:92t

Antipseudomonal agents, 16:193t, 194t

Antipyretics
for acute bacterial rhinosinusitis, 9:103t, 107,
10:119t
for influenza, 15:186

Antithrombotic agents, 5:63-64

Antivert. *See* Meclizine

Antiviral medications
for influenza, 26:324
recommended daily dosage, 26:326t
trade names, routes of administration, precautions,
and toxicities, 26:325t

Apioloic appendagitis, primary, 23:289

Apligraf (bioengineered tissue), 14:163

Appendagitis, primary apioloic, 23:289

Appendicitis
acute, 23:284, 287
in older patients, 23:284
in pediatric patients, 22:276-277
in pregnant patients, 23:287

Apresoline (hydralazine), 24:297, 297t, 298

Arcanobacterium, 21:263

Arcanobacterium haemolyticum, 21:265t

Ardeparin, 12:141t

ARF. *See* Acute rheumatic fever

Arm weakness, 6:72t

Armstrong, Michael, 9:102, 10:121

Arsenic, 23:289

Arterial blood gases, 11:129

ASA. *See* American Stroke Association

ASCAP. *See* Antibiotic Selection for Community-
Acquired Pneumonia Consensus Panel

Ascending cholangitis, 23:283

Asians, 17:214

Aspergillus fumigatus, 20:247

Aspirin (acetylsalicylic acid)
for DVT and PE prevention, 12:144
for influenza, 15:186
for prevention of preeclampsia, 24:300
for prevention of stroke, 5:62-63, 6:74
for ST-elevation MI, 8:92t, 93t, 96t

ASSENT-4 PCI trial, 8:97

Asthma exacerbations, acute, 1:7

Ataxic hemiparesis, 5:65

**ATBS (Antibiotic Therapy for Bacterial Sinusitis)
Clinical Consensus Panel**
issues, topics, and guidelines evaluated and analyzed
by, 9:104t
recommendations, 9:110
summary of guidelines and recommendations,
10:120-121

Year 2004 Report® and Treatment
Recommendations, 9:101-110, 10:113-121

Atenolol (Tenormin), 24:298

**Atlantic Cardiovascular Patient Outcomes
Research Team (C-PORT)**, 8:91-94

ATLS. *See* Advanced trauma life support

Atrial fibrillation, 5:61

Atropine, 19:241

ATS. *See* American Thoracic Society

Auditory barotrauma, 4:45

Auditory injuries, blast-related, 4:49t, 50, 50t

Augmentin. *See* Amoxicillin/clavulanate

Availability, S04180:5t

Aventis Pasteur, 26:328, 329

Aviane, 25:312t

Azalides, 9:107

Azasan. *See* Azathioprine

Azathioprine (Azasan, Imuran)
immunosuppressive therapy with, 2:16
side effects, 23:286

Azithromycin (Zithromax)
for acute bacterial rhinosinusitis, 9:104, 109t, 110,
10:114-115, 120t, 121
for acute otitis media, 20:250t
for community-acquired pneumonia, 16:192,
194t-195t
for folliculitis, 13:152
for furunculosis with surrounding cellulitis or
systemic signs, 13:152
for human and mammalian bites, 14:167t
for pharyngitis, 21:265t
regimens for GABHS pharyngitis, 21:266t
short-course therapy, 10:114

Aztreonam, 16:193t

B

Bacillus subtilis, 14:165

Bacitracin (Baciguent), 17:212

Bacterial infections
acute bacterial rhinosinusitis, 9:101-110, 10:113-121
community-acquired pneumonia, 16:193t
diabetic foot ulcer infections, 14:162-163, 163-164
gram-negative, 9:105, 109-110, 110t, 10:115, 121t,
13:150, 151t
gram-positive, 13:150
in renal transplant recipients, 2:18
of skin, 13:153-154
of skin and soft-tissue, 13:149-150, 14:162
of skin appendices, 13:152-153

Bacterial rhinosinusitis, acute
AAOHS guidelines, 10:115
antibiotic selection for, 9:106-110
antibiotic therapy for, 9:101-110, 103t, 10:113-121
antimicrobial treatment issues, 9:104
definition of, 9:102-103
diagnosis of, 9:103-104, 10:117
differential diagnosis of, 9:105t, 10:117
drug resistance in, 9:104-105
epidemiological patterns, 9:104-105

microbiology of, 9:107
patient evaluation in, 10:117-119
referral triggers, 9:105-106, 106t
risk factors and clinical conditions predisposing to or
associated with, 9:104t
short-course therapy for, 10:113-114
signs and symptoms associated with, 9:105, 105t
treatment guidelines, 9:109t, 110t, 10:120t, 121t
Year 2004 ATBS Clinical Consensus Panel Report®
and Treatment Recommendations, 9:101-110,
10:113-121

Bacterial sinusitis
diagnosis of, 9:103, 107t
evaluation of, 9:107t
principles of diagnosis and evaluation in, 9:106

Bacteriology
of cellulitis, 13:153t, 154
of mammalian bites, 14:164
of skin and soft-tissue infections, 13:150-151

Bacteroides
in cat bites, 14:166
in chronic suppurative otitis media, 20:249
in human bite wounds, 14:168
in mammalian bite wounds, 14:164, 164t
in necrotizing fasciitis, 14:169, 170t
in peritonsillar abscess, 21:265
in pharyngitis, 21:263

Bactrim. *See* Trimethoprim/sulfamethoxazole
(TMP-SMX)

Barotrauma
auditory, 4:45
precautions, 4:53
pulmonary, 4:46

Barr Pharmaceuticals, 25:317-318

Bartonella henselae, 14:166-167

Base rates, neglect of, S04180:5t

Battery ingestion, 3:31

**Bavarian Reperfusion Alternatives Evaluation
(BRAVE) trial**, 8:97

Becaplermin (platelet-derived growth factor gel),
14:163

Bell's palsy, 21:261-263
influenza vaccine and, 26:327
stroke mimic, 5:59

Benadryl. *See* Diphenhydramine

Benzocaine, 17:209t

Benzodiazepines, 19:240-241

Benzyl alcohol, 17:209

Beta-blockers, 8:92t

Beta-lactams
for acute bacterial rhinosinusitis, 9:109, 109t, 110,
110t, 10:120t, 121, 121t
antibiotic selection for, 16:195t
for community-acquired pneumonia, 16:192, 193t

Bias, confirmatory, S04180:5t

Biaxin. *See* Clarithromycin

Bile peritonitis, 23:283

Bilevel positive airway pressure ventilation, 1:2

Biliary tract disease
in liver transplant recipients, 2:21

<p>in older patients, 23:282-284 in pediatric patients, 22:278 in pregnant patients, 23:287</p> <p>Bioengineered tissue (Apligraf), 14:163</p> <p>BiPAP. <i>See</i> Bilevel positive airway pressure ventilation</p> <p>Bites cat, 14:164, 164t, 165-166 dog, 14:164-165, 164t facial wound repair, 17:207 ferret, 14:168 human, 14:164, 168, 168t, 169 iguana, 14:167-168 mammalian, 14:164-169 non-venomous reptilian, 14:167-168 pediatric wounds, 19:239</p> <p>Blair, Elizabeth, 9:102, 10:121</p> <p>Blast injuries, 4:41-53 disposition, 4:53 evaluation of, 4:49, 52f fatal, 4:48-49 historical locations of U.S. bomb incidents, 4:41, 43f immediate death, 4:48-49 laboratory studies, 4:49 management of, 4:49 mechanism of, 4:42, 45 miscellaneous effects, 4:48 overpressure and effects, 4:43, 44t pathophysiology of, 4:45-49 precautions, 4:53 primary, 4:42, 43f, 45-47 quaternary, 4:48 radiographic studies, 4:49 secondary, 4:42, 43f, 47-48, 47f stand-off distances, 4:49, 51t tertiary, 4:42, 43f, 48 treatment of, 4:50-53 wound management, 4:53</p> <p>Blast lung, 4:42, 45, 46, 46f, 50</p> <p>Blastomyces dermatitidis, 21:263</p> <p>Bleeding complications in liver transplant recipients, 2:21 in renal transplant recipients, 2:17</p> <p>Blood pressure in ischemic stroke, 6:73 pregnancy-induced hypertension, 24:293-294 recommended limits, 5:61</p> <p>Blood pressure control while breast-feeding, 24:298 in pregnancy, preeclampsia, eclampsia, and HELLP, 24:295-298, 296f</p> <p>Blowout fracture, 18:224, 225f</p> <p>Boarding, S04180:2</p> <p>Boil (furunculosis), 13:152</p> <p>Bomb injuries. <i>See</i> Blast injuries</p> <p>Bomb stand-off distances, 4:49, 51t</p> <p>Bonine. <i>See</i> Meclizine</p> <p>Bougenage method of esophageal foreign body removal, 3:34</p> <p>Bowel obstruction</p>	<p>in cancer patients, 23:286 in older patients, 23:282</p> <p>Brain injury, 4:47</p> <p>BRAVE trial. <i>See</i> Bavarian Reperfusion Alternatives Evaluation trial</p> <p>Breast-feeding, 24:298</p> <p>Brevibloc (esmolol), 23:285</p> <p>British Columbia, 15:181</p> <p>British Thoracic Society, 16:190</p> <p>Brownfield v. Daniel Freeman Marina Hospital, 25:317</p> <p>Bullous impetigo, 13:153</p> <p>Bullous myringitis, 20:249</p> <p>Bupivacaine (Marcaine) chemical classification of, 17:209, 209t for facial wound repair anesthesia, 17:209</p> <p>Burns chemical, 18:222-223 esophageal, 3:31 facial, 17:204-205 orbital, 18:222-223 thermal, 18:222-223</p> <p>Button battery ingestion, 3:31</p> <p>C</p> <p>C-4, 4:42-43</p> <p>Calan (verapamil), 24:297t</p> <p>California Court of Appeals, 25:317 emergency contraception in, 25:318 Therapeutic Abortion Act, 25:317</p> <p>Caloric requirements, 14:173</p> <p>Campylobacter, 13:151t</p> <p>Campylobacter fetus, 13:151t</p> <p>CAMRSA. <i>See</i> Community-acquired methicillin-resistant <i>Staphylococcus aureus</i></p> <p>CAN. <i>See</i> Chronic allograft nephropathy</p> <p>Canada epidemics of influenza in, 15:183 severe acute respiratory syndrome in, 15:178, 182</p> <p>Canalicular injuries, 18:221</p> <p>Cancer acute abdominal pain in, 23:286 in organ transplant recipients, 2:16</p> <p>Candida in human bite wounds, 14:168t in pharyngitis, 21:263, 265t</p> <p>CAP. <i>See</i> Community-acquired pneumonia</p> <p>Capnocytophaga canimorsus in dog bites, 14:165 risk factors for, 13:151t</p> <p>Capoten. <i>See</i> Captopril</p> <p>CAPTIM trial. <i>See</i> Comparison of Angioplasty and Prehospital Thrombolysis in Acute MI trial</p> <p>Captopril (Capoten) for ischemic stroke, 6:73 usage in pregnancy, 24:297t</p> <p>Carbacaïne (mepivacaine), 17:209</p> <p>Carbuncle, 13:152-153</p>	<p>Cardiac catheterization, 8:93t</p> <p>Cardiac evaluation, 2:20</p> <p>Cardiac injury, 4:47</p> <p>Cardiac surgery, 8:91-94</p> <p>Cardiopulmonary resuscitation, 4:49</p> <p>Cardiovascular disease, 2:18</p> <p>Cardiovascular injury, explosion-related, 4:49t, 50t</p> <p>Carotid artery disease, asymptomatic, 5:61</p> <p>Carotid artery rupture, 21:270</p> <p>Carotid dissection, 5:60</p> <p>Carotid TIAs, 5:64</p> <p>CAST. <i>See</i> Chinese Acute Stroke Trial</p> <p>Cat bites, 14:164, 165-166 facial wound repair, 17:207 infectious organisms in, 14:164t pediatric, 19:239 risk stratification, 14:164 treatment of, 14:166</p> <p>Cat scratch disease, 14:166-167</p> <p>Cat scratches, 14:165-166</p> <p>Catapres (clonidine), 24:297t</p> <p>Catholic hospitals, 25:315-317</p> <p>Caucasians, 5:62</p> <p>Cauliflower ear, 19:236</p> <p>Caustic ingestion, 22:278</p> <p>CDC group DF-2, 14:165</p> <p>CDC Nonoxidizer 1 group (NO-1), 14:165</p> <p>Cecal volvulus, 23:282</p> <p>Ceclor (cefactor), 20:250t</p> <p>Cedax. <i>See</i> Cefibuten</p> <p>Cefactor (Ceclor), 20:250t</p> <p>Cefdinir (Omnicef), 20:250t</p> <p>Cefepime, 16:193t, 194t</p> <p>Cefixime (Suprax) for acute bacterial rhinosinusitis, 9:107 for acute otitis media, 20:250t</p> <p>Cefotaxime (Claforan) for community-acquired pneumonia, 16:191, 192, 193t for peritonsillar abscess, 21:266 susceptibility of pneumococcal isolates to, 16:191</p> <p>Cefoxitin (Mefoxin) for diverticular disease, 23:285 for human and mammalian bites, 14:167t for peritonsillar abscess, 21:266</p> <p>Cefpodoxime (Vantin) for acute bacterial rhinosinusitis, 9:109, 109t, 110t, 10:120t, 121t for acute otitis media, 20:250t for community-acquired pneumonia, 16:193t for otitis media, 20:249</p> <p>Cefprozil (Cefzil) for acute otitis media, 20:250t for community-acquired pneumonia, 16:193t</p> <p>Ceftazidime, 16:194t</p> <p>Ceftibuten (Cedax) for acute bacterial rhinosinusitis, 9:109t, 110t, 10:120t, 121t for acute otitis media, 20:250t</p> <p>Ceftin. <i>See</i> Cefuroxime</p>
---	--	--

Ceftriaxone (Rocephin)

for acute otitis media, 20:249, 250t
for cheek wound repair, 18:227
for community-acquired pneumonia, 16:191, 192, 193t, 194t-195t
for necrotizing fasciitis, 14:172t
for otitis media, 20:249
for pharyngitis, 21:265t
susceptibility of pneumococcal isolates to, 16:191

Cefuroxime (Ceftin)

for acute bacterial rhinosinusitis, 9:109, 109t, 110t, 10:116-117, 120t, 121t
for acute otitis media, 20:250t
for community-acquired pneumonia, 16:193t, 195t
for otitis media, 20:249
for sialadenitis, 20:256

Cefzil. *See* Cefprozil**Cellulitis, 13:153-154**

around the anus, 13:155
bacteriology of, 13:153t, 154
epidemiology of, 13:153t, 154
around the eye, 13:155
furunculosis with surrounding cellulitis, 13:152
orbital, 13:155
perianal, 13:155
periorbital, 13:155
of specific areas, 13:155

Center for Reproductive Law and Policy, 25:317**Centers for Disease Control and Prevention (CDC)****case definition of SARS, 15:182****Drug-Resistant *Streptococcus pneumoniae***

Working Group (CDC-DRSPWG), 9:105, 109-110, 16:190

guidelines for antibiotic use in sinusitis, 10:119
practice guidelines for bacterial respiratory tract infections, 10:120t

Central nervous system infection, 2:16-17**Cepacol (menthol and benzocaine), 21:263****Cephalexin (Keflex)**

for acute otitis media, 20:250t
for ear lacerations, 19:236
for folliculitis, 13:152
for frontal sinus fractures, 18:219
for furunculosis with surrounding cellulitis or systemic signs, 13:152
for human and mammalian bites, 14:167t

Cephalosporins

for acute otitis media, 20:250t
for folliculitis, 13:152
for furunculosis with surrounding cellulitis or systemic signs, 13:152
for necrotizing fasciitis, 14:172t
regimens for GABHS pharyngitis, 21:266t
short-course therapy, 10:114

Cerebral blood flow, 6:72**Cerebrospinal fluid leaks/fistulae, 17:205****Cerebrovascular accident, 5:61****Charcot's triad, 23:283****Cheek wound repair, 18:227****Chemical burns, orbital, 18:222-223****Chest pain, 11:127, 128t****Chest x-rays**

in pediatric foreign body ingestion, 3:32-33, 32f
in pulmonary embolism, 11:130

CHF. *See* Congestive heart failure**Children.** *See* Pediatric patients**Chin lacerations**

pediatric, 19:241
repair of, 19:233

China, 15:178**Chinese Acute Stroke Trial (CAST), 6:74****Chiron, 26:328, 329****Chlamydia, 21:263*****Chlamydia pneumoniae***

in community-acquired pneumonia, 16:189, 192
in pharyngitis, 21:265t
testing for, 16:195

Chlamydia trachomatis*, 21:265t*Chlamydia, 16:193****Cholangitis, 23:283****Cholecystitis**

acute, 23:282-284
in pregnant patients, 23:287

Cholelithiasis, 23:282-283, 284, 287**Cholesteatoma, 20:251t****Chronic allograft nephropathy, 2:18****Chronic hypertension, 24:295t****Chronic neuromuscular diseases, 1:8****Chronic obstructive pulmonary disease, 1:4-5****Chronic paronychia, 13:156****Chronic suppurative otitis media, 20:249****Cigarette smoking, 5:61-62****Cincinnati Prehospital Stroke Scale (CPSS), 6:70, 72t****Ciprofloxacin (Cipro, Cipro HC Otic, Ciprodex)**

for acute bacterial rhinosinusitis, 10:117
for community-acquired pneumonia, 16:193t, 194t
for diverticular disease, 23:285
for hot tub folliculitis, 13:152
for human and mammalian bites, 14:167t
for otitis externa, 20:248t
for pharyngitis, 21:265t
topical preparations, 20:248t

Claforan. *See* Cefotaxime**Clarithromycin (Biaxin)**

for acute bacterial rhinosinusitis, 9:109t, 110, 10:120t, 121

for acute otitis media, 20:250t

for community-acquired pneumonia, 16:192
regimens for GABHS pharyngitis, 21:266t

Clavulanate. *See* Amoxicillin/clavulanate;

Ticarcillin/clavulanate

Cleaning, facial wound, 17:210-211**Clenched fist syndrome, 14:168-169, 168f****Clindamycin (Cleocin, Dalacin C)**

for acute cholecystitis, 23:284
for community-acquired pneumonia, 16:193t, 194t-195t
for furunculosis, 13:152
for human and mammalian bites, 14:167t

for mandible fracture, 19:234-235

for necrotizing fasciitis, 14:172t

for otitis media, 20:249

for peritonsillar abscess, 21:266

for pharyngitis, 21:265t

regimens for GABHS pharyngitis, 21:266t

for sialadenitis, 20:256

for volvulus, 22:275

Clinical islet transplantation, 2:22**Clinical practice guidelines, S04180:5****Clonazepam, 20:251t****Clonidine (Catapres), 24:297t****Clopidogrel**

for prevention of stroke, 5:63
for ST-elevation MI, 8:92t, 93t

Clostridial necrotizing fasciitis

antimicrobial agents in treatment of, 14:172t
treatment of, 14:172

***Clostridium* spp.**

in necrotizing fasciitis, 14:169, 170, 170t
risk factors for, 13:151t

Clotrimazole (Lotrimin)

for malignant otitis externa, 20:247
for pharyngitis, 21:265t

Cloxacillin, 13:152**Clumsy hand, 5:65****CMV.** *See* Cytomegalovirus**Coagulation studies, 6:71****Cocaine**

chemical classification of, 17:209t
and ischemic stroke, 5:62

Cognitive limitations, S04180:4-5**Coin ingestion**

chest x-rays in, 3:32-33, 32f
management of, 3:35

Cold, common. *See* Viral upper respiratory tract infections**Combat medicine, 4:42****Community-acquired methicillin-resistant**

***Staphylococcus aureus*, 13:150-151**

in diabetic foot ulcers, 14:163
treatment of, 14:163

Community-acquired pneumonia, 16:189-196

antibiotic selection for, 16:194t-195t
antibiotic therapy for, 16:191-195, 193t, 194t-195t, 196

bacterial, 16:193t

discharge criteria for, 16:196

disposition from ED, 16:189-190

IDSA Practice Update Guidelines, 9:109t, 10:120t

initial empiric therapy for, 16:193t

newer antibiotics for, 16:191-195

quality indicators in, 16:195-196

severity index, 16:190, 191t-192t

short-course therapy for, 10:114

testing for specific pathogens, 16:195

therapeutic guidelines for, 16:190

treatment guidelines, 9:109-110

Year 2004 ASCAP guidelines for management of, 16:194t-195t

Comparison of Angioplasty and Prehospital Thrombolysis in Acute MI (CAPTIM) trial, 7:84, 8:94, 95

Complete blood count, 6:71

Composition C-4, 4:42-43

Computed tomography
Caldwell view, 17:206
indications of poor outcome after thrombolytic administration, 6:71, 73t
in ischemic stroke, 6:71-72, 73
in pulmonary embolism, 11:131
in sinusitis, 10:117-119

Computed tomography angiography
in ischemic stroke, 6:72
in pulmonary embolism, 11:131, 132

Confirmatory bias, S04180:5t

Congenital aganglionic megacolon, 22:277

Congestive heart failure
noninvasive ventilation in, 1:5-7
and pulmonary embolism, 11:127

Conscious sedation, 17:209

Constipation, 23:286

Consult for facial wound repair, 17:207-208, 207t

Continuous positive airway pressure ventilation, 1:2

Contraception
emergency, 25:309-318, 311t, 313t
postcoital, 25:310

COPD. *See* Chronic obstructive pulmonary disease

Core Measures (JCAHO), S04180:6

Corneal abrasions/foreign bodies/ulcers, 18:221-222

Corner sutures, 17:212, 213f

Coronary artery disease, 2:19-20

Coronary artery stenting, 8:89-90

Cortane B, 20:248t

Cortef (hydrocortisone), 23:289

Corticosporin TC Otic, 20:248t

Corticosteroids
for Bell's palsy, 21:262
immunosuppressive therapy with, 2:16

Cortisporin Otic, 20:248t

Corynebacterium, 14:169, 170t

Corynebacterium diphtheriae
in laryngitis, 21:267
in pharyngitis, 21:263, 265t

Corynebacterium minutissimum, 13:153

Corynebacterium ulcerans, 21:263

Cough
general management principles, 9:108t, 10:118t
in pulmonary embolism, 11:127, 128t
treatment options, 9:108t, 10:118t

Cough suppressants, 9:108t, 10:118t

Coxsackie virus, 21:264t

Cozaar. *See* Losartan

CPAP. *See* Continuous positive airway pressure ventilation

CPGs. *See* Clinical practice guidelines

C-PORT. *See* Atlantic Cardiovascular Patient Outcomes Research Team

CPSS. *See* Cincinnati Prehospital Stroke Scale

Crackles, 11:128, 128t

Cranial nerve injuries, 17:205

Craniofacial disjunction, 18:229-230, 229f

Cryptococcus neoformans, 21:263

Cryselle, 25:312t

CSD. *See* Cat scratch disease

CSF rhinorrhea, 18:226-227

C-spine injury, 17:205

CT. *See* Computed tomography

CTA. *See* Computed tomography angiography

Culture of safety, S04180:5

Cyclosporine, 2:15, 16t

Cyclotrimethylenetrinitramine, 4:42-43

Cystitis, 23:288

Cytomegalovirus
clinical presentation, diagnostic tests, and treatment of, 21:264t
in liver transplant recipients, 2:21
in organ transplant recipients, 2:14-15

Cytovene (ganciclovir), 21:264t

D

Dalacin C. *See* Clindamycin

Dalteparin
for deep vein thrombosis, 12:139, 140
dosing for DVT with or without PE, 12:141t
for DVT and PE prevention, 12:144t

Dance's sign, 22:276

Daniel Freeman Marina Hospital, Brownfield v., 25:317

Danish Trial in Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2), 8:94

DDI (didanosine), 23:286

D-dimer, 11:128-129, 132

Death, immediate, 4:48-49

Debridement of facial wounds, 17:210-211

Decadron. *See* Dexamethasone

Decongestants
for acute bacterial rhinosinusitis, 9:103t, 107, 10:119t
for upper respiratory tract infections and sinusitis, 9:108t, 10:118t

Deep neck infections, 21:268-270

Deep stitches
horizontal, 17:212, 213f
technique for, 17:212, 212f

Deep structure injury
ear, 19:237
facial, 18:219
midface, 18:227-228
nasal, 18:226

Deep vein thrombosis
epidemiology of, 11:126
evaluation for, 11:130-131, 132
inferior vena caval filters for, 12:143
prevention of, 12:144, 16:196
treatment options, 12:139, 140
upper extremity, 11:127, 12:143

warfarin therapy for, 12:143

Delta-Cortef. *See* Prednisone

Deltasone. *See* Prednisone

Dementia, 5:60

Dental trauma, 19:238-239

Dermabond, 17:213

Dermatobia hominis, 13:152

Dexamethasone (Decadron, Dexone, Dexasone, Hexadrol)
for acute adrenal crisis, 23:289
for HELLP syndrome, 24:304
topical preparations, 20:248t

Dexon (polyglycolic acid suture), 17:211

Dextromethorphan, 9:108t, 10:118t

DF-2, 14:165

Diabetes mellitus
cellulitis associated with, 13:154
foot ulcer infections in, 14:162-163, 163-164
and ischemic stroke, 5:61

Diabetic foot ulcer infections
diagnosis of, 14:163-164
location of, 14:162, 163t
minor, 14:163
prognosis for, 14:163-164
serious, 14:163
treatment of, 14:163-164

Diazepam (Valium)
dosage regimen for preeclampsia and eclampsia, 24:298t, 302
for eclampsia, 24:302
for vestibular neuronitis, 20:251, 251t

Didanosine (DDI) (Videx, ddI), 23:286

Diffusion-weighted imaging, 6:72

Diflucan (fluconazole), 21:265t

Dilantin. *See* Phenytoin

Dimenhydrinate (Dramamine), 25:314t

Diovan (valsartan), 24:297t

Diphenhydramine (Benadryl)
for facial wound repair anesthesia, 17:209
for nausea after EC, 25:314t
as vestibular suppressant, 20:251t

Diplopia, 18:224-225

Dislocation, mandible, 19:235

Distal fingers and toes, 13:156

Diurnal variations, 5:60-61

Diversion, S04180:2

Diverticular disease, 23:284-285

Diverticulitis, 23:284

Dog bites, 14:164-165
facial wound repair, 17:207
infectious organisms in, 14:164t, 165
pediatric, 19:239
treatment of, 14:166

Domeboro Otic, 20:248t

Doxycycline (Vibramycin)
for acute bacterial rhinosinusitis, 9:109t, 110, 10:120t, 121
for cheek wound repair, 18:227
for community-acquired pneumonia, 16:193t
for pharyngitis, 21:265t

Dramamine (dimenhydrinate), 25:314t
Droxia (hydroxyurea), 23:286
Drug resistance
in acute bacterial rhinosinusitis, 9:104-105, 109-110, 110t
antibiotic, 16:191-192
community-acquired methicillin-resistant *S. aureus*, 13:150-151, 14:163
drug-resistant *S. pneumoniae*, 16:191-192
pneumococcal, 20:249, 249t
Drugs. See Medications
Duodenal ulcers, 23:286
DVT. See Deep vein thrombosis
DWI. See Diffusion-weighted imaging
Dysarthria-clumsy hand, 5:65
Dyspnea, 11:127, 128t

E

Ear
anatomy of, 20:245-246
foreign bodies in, 20:249-251
nerve blocks for, 17:210
Ear, nose, and throat disorders, 20:245, 21:261-270
Ear pain, 20:246, 247t
Ear trauma, 19:235-237
blast-related injuries, 4:45, 50
laceration repair, 19:236-237, 236f
EBV. See Epstein-Barr virus
EC. See Emergency contraception
ECASS. See European Cooperative Acute Stroke Study
Ecchymosis, thoracic, 4:46
ECG. See Electrocardiography
Echocardiography
in pulmonary embolism, 11:130
transesophageal, 11:130
Eclampsia, 24:294, 300-302
anticonvulsant dosage regimens for, 24:298t
blood pressure control in, 24:295-298
clinical presentation of, 24:301-302
definition of, 24:295t, 301
differential diagnosis of, 24:300t, 301
ED management of, 24:301-302
ED management pitfalls, 24:303t
management of, 24:302
ECMO. See Extracorporeal membrane oxygenation
ECPs. See Emergency contraception pills
Ecthyma, 13:153
Ectopic pregnancy, 23:287-288
with emergency contraception, 25:314
Edema
acute pulmonary, 1:5-7
differential diagnosis of, 24:300t, 301
Effusion, otitis media with, 20:248
EIA. See Enzyme immunoassay
Eikenella corrodens
in cellulitis, 13:153t, 154
in human and mammalian bites, 14:167t
in human bite wounds, 14:168, 168t

risk factors for, 13:151t
Elder abuse and neglect, 23:286
Electrocardiography
in ischemic stroke, 6:71
prehospital transmission, 7:83-85
in pulmonary embolism, 11:129-130, 130t
ST-elevation MI on, 7:82
Electrolytes, serum, 6:71
Electronic medical record systems, S04180:6
Elspar (L-asparaginase), 23:286
Embolectomy, 12:142-143
Emergency contraception, 25:309-310, 310-311
access to, 25:315
contraindications to, 25:313
definition of, 25:309-310
ED management, 25:315
ED strategy for administration, 25:315, 316f
factors contributing to lack of use, 25:315
Guidelines for Catholic Hospitals Treating Victims of Sexual Assault, 25:317
indications for, 25:310, 311t
mechanism of action, 25:311-312
options, 25:318
oral, 25:311, 312t
OTC status, 25:317-318
Ovulation Approach or Peoria Protocol for, 25:317
Pregnancy Approach to, 25:317
recommendations for, 25:311
resources for physicians and patients, 25:313t
side effects of, 25:313-315
special considerations for, 25:315-317
strategies to reduce risk of nausea after, 25:314, 314t
timing of administration, 25:312-313
Emergency contraception pills, 25:311
Emergency department evaluation. See Evaluation
Emergency departments
diversionary status, S04180:2
errors in, S04180:2-3
influenza vaccination, 26:329
leaving without treatment from, S04180:2
overcrowding of, S04180:1-2
prevention of influenza, 15:186
recommended actions for reduction of error, S04180:5-6
as system under assault, S04180:1-2
visit volumes, S04180:1
Emergency ultrasound. See Ultrasound
Emerman, Charles, 9:102, 10:121
EMR systems. See Electronic medical record systems
Enalapril (Vasotec), 24:297t
Encephalitis, 5:60
Encephalopathy, hypertensive, 5:60
Endoscopic retrograde cholangiopancreatography, 23:284
Endoscopy, 3:33
for foreign body removal, 3:34
Endotracheal intubation, 1:1
Enoxaparin
for acute MI, 8:89
for deep vein thrombosis, 12:140

for DVT and PE prevention, 12:144, 144t
for DVT with or without PE, 12:141, 141t
for pulmonary embolism, 12:141t
for ST-elevation MI, 8:92t, 93t, 96t
for venous thromboembolism, 12:139
Enpresse, 25:312t
Enterobacter
in dog bites, 14:165
in necrotizing fasciitis, 14:169, 170t
Enterococcus, 14:169, 170t
Enterococcus faecalis, 21:270
Enzyme immunoassay, 26:324
Enzyme-linked immunosorbent assay, 11:129, 132
EP. See Ectopic pregnancy
EPAP. See Expiratory positive airway pressure
Epidemics, 15:183, 26:321, 322, 323
Epiglottitis, 21:267-268
Epinephrine
for epistaxis, 20:253t
for facial wound repair sedation, 17:209
Epistaxis, 20:252-254, 253t
Epstein-Barr virus
clinical presentation, diagnostic tests, and treatment of, 21:264t
in organ transplant recipients, 2:15
Eptifibatid (Integrilin)
for acute MI, 8:96
for ST-elevation MI, 7:85, 8:92t, 96
Errors
definition of, S04180:3, 3t
recommended actions for reduction of, S04180:5-6
systems approach to reduction of, S04180:3
types of, S04180:4
Ertapenem, 16:193t
Erysipelas, 13:155
Erysipelothrix rhusiopathiae
in cellulitis, 13:153t, 154
risk factors for, 13:151t
Erythrasma, 13:153
Erythromycin
for community-acquired pneumonia, 16:192
for erythrasma, 13:153
for necrotizing fasciitis, 14:172t
regimens for GABHS pharyngitis, 21:266t
Erythromycin/sulfisoxazole (Pediazole), 20:250t
Escherichia coli
in chronic suppurative otitis media, 20:249
in epiglottitis, 21:267
in Ludwig's angina, 21:270
in necrotizing fasciitis, 14:169, 170t
risk factors for, 13:151t
in sialadenitis, 20:255
Escherichia coli 0157:H7, 22:277
Esmolol (Brevibloc), 23:285
Esophageal burns, 3:31
Esophageal foreign bodies
algorithm for management of, 3:36f
anatomy and physiology involved with, 3:29-30
detection methods, 3:33
management of, 3:35

medications used in management of, 3:34-35

in pediatric population, 3:29-37

removal methods, 3:33-34

Estragen

for emergency contraception, 25:311

and ischemic stroke, 5:62

Ethical and Religious Directives for Catholic

Health Care Services Directive 36, 25:316-317

Ethinyl estradiol

for emergency contraception, 25:310-311

oral EC options, 25:311, 312t

ETI. *See* Endotracheal intubation

Etidocaine, 17:209t

European Cooperative Acute Stroke Study

(ECASS), 6:71-72, 74

Evaluation

heart transplant, 2:20

liver transplant, 2:22

pancreas transplant, 2:23-24

renal transplant, 2:18-19

Expiratory positive airway pressure, 1:2

Explosion-related injuries. *See* also Blast injuries

evaluation of, 4:52f

overview, 4:50t

signs and symptoms of, 4:49, 49t

Explosions

medium of occurrence, 4:44-45

pressure-time history of, 4:43, 44f

Explosives, 4:42-44

Extracorporeal membrane oxygenation, 12:143

Extremity injuries, explosion-related, 4:50t

Eye

cellulitis around, 13:155

secondary blast injuries, 4:47-48, 48f

Eyebrow and eyelid wound repair, 18:219-221

F

Face

nerve blocks for, 17:209-210

skin tension lines, 17:211, 211f

Facial burns, 17:204-205

Facial droop, 6:72t

Facial fractures

associated injury, 17:205

in facial trauma, 17:206

force of gravity required for, 17:206, 206t

overview of, 17:205-206

pediatric, 19:241

Facial lacerations, 17:207-208

Facial nerve, 18:227, 227f, 228

Facial nerve injury, 18:228-229

Facial nerve palsies, 21:261-263

Bell's palsy, 5:59

evaluation of, 6:72t

Facial trauma, 17:201-202, 18:217-230, 19:233-241

airway management and, 17:202-204, 203t

deep structure injury, 18:219

life-threatening, 17:202-205, 203t

midface, 18:227-230

pediatric, 19:239-241

Facial wound repair, 17:206-214

anesthesia, 17:208-209

bite wounds, 17:207

closure/suture technique, 17:211-212

consult for, 17:207-208, 207t

hemostasis, 17:211

how to make wound edges even, 17:211-212, 212f

irrigation and debridement, 17:210-211

lacerations, 17:207-208

primary closure, 17:207

recommendations for, 17:208t

sedation for, 17:209

suture alternatives, 17:212-214

technique for deep stitches, 17:212, 212f

tips on, 17:208

wound care after ED, 17:214

Facilitated percutaneous coronary intervention,

8:96-97

Famciclovir (Famvir), 21:264t

Familial Mediterranean fever, 23:289

Fatal blast injuries, 4:48-49

Fatty liver, acute, 24:300

Felon, 13:156

Fentanyl (Sublimaze)

for facial wound repair sedation, 17:209

for pediatric patients, 19:240

Ferret bites, 14:168

Fever

familial Mediterranean, 23:289

in pulmonary embolism, 11:128t

rheumatic, 21:264

Fibrillation, atrial, 5:61

Fibrinolytic therapy

for acute MI, 8:89

combined with angioplasty, 8:97

combined with GPIIb/IIIa inhibitors, 7:85

indications for, 8:89

prehospital, 7:83-85

for ST-elevation MI, 7:83, 85, 8:89, 91, 93t, 96t

Fingers, distal, 13:156

Fingerstick glucose, 6:70-71

Fistula, pancreas transplant, 2:23

FK 506 (tacrolimus), 2:15

Flagyl. *See* Metronidazole

Florazole-ER. *See* Metronidazole

Floxin. *See* Ofloxacin

Fluconazole (Diflucan), 21:265t

Flumadine (rimantadine)

for influenza, 15:184, 185t, 26:324

precautions and toxicity, 26:325t

recommended daily dosage, 26:326t

FluMist (influenza virus vaccine live), 15:184,

26:328

Fluoroquinolones

for acute bacterial rhinosinusitis, 9:107, 109, 109t,

110, 10:115-117, 120t, 121

for community-acquired pneumonia, 16:192, 193t,

195t

extended spectrum, 10:115-117

short-course therapy, 10:114

Fluvirin (influenza vaccine), 26:328

Fluzone (influenza vaccine), 26:328

FMMF. *See* Familial Mediterranean fever

Fogarty catheter method for nasal foreign bodies,
20:254-255

Foley catheter method

for esophageal foreign body removal, 3:33, 34

for nasal foreign body removal, 20:254-255

Folliculitis, 13:152

Foot ulcer infections, 14:162-163, 163-164

Forehead

nerve blocks for, 17:209

sutures, 18:219, 220f

trauma to, 18:217-219

wound repair, 18:219

Foreign bodies

corneal, 18:222

ear, 20:249-251

esophageal, 3:29-37

intraocular/orbital, 18:223

nasal, 20:254-255

Foreign body ingestion

algorithm for, 3:36f

anatomy and physiology involved with, 3:29-30

detection methods, 3:33

epidemiology of, 3:30

management of, 3:35

medications used in management of, 3:34-35

in pediatric population, 3:29-37

radiological studies, 3:32-33, 32f

removal methods, 3:33-34

risk factors for, 3:30

signs of, 3:31

symptoms of, 3:32

types of foreign bodies ingested, 3:30-31, 31t

Foscarnet (Foscavir), 21:264t

Fowl plague, 26:321

Fractures

blowout, 18:224, 225f

facial, 17:205-206, 19:241

frontal sinus, 18:219

LeFort, 18:229-230, 229f

mandible, 19:233-234, 235f

maxillary, 18:229-230

maxillary sinus, 18:230

midface, 18:229-230

nasal, 18:226

orbital, 18:224-225

panfacial, 18:229

pyramidal, 18:229, 229f

tooth, 19:239

tripod, 18:230

zygoma, 18:230

Fragment injuries

secondary blast injuries, 4:47, 48f

wound management, 4:53

Frontal sinus fracture, 18:219

Functional hemiplegia, 5:60

Furunculosis (boil), 13:152

Fusobacterium

- in human bite wounds, 14:168t
- in mammalian bite wounds, 14:164, 164t
- in necrotizing fasciitis, 14:169, 170t
- in pharyngitis, 21:263

G

Gabapentin (Neurontin), 23:289

GABHS. *See* Group A beta-hemolytic Streptococcus

Gallstones, 23:283, 284

Ganciclovir (Cytovene), 21:264t

Garamycin. *See* Gentamicin

GAS. *See* Group A streptococcus

Gastric ulcers, 23:286

Gastric volvulus, 23:282

Gastroenteritis, acute, 22:277

Gastroesophageal reflux disease, 23:288

Gastrointestinal damage

- blast injuries, 4:46, 51-52
- explosion-related injuries, 4:49t, 50t

Gitifloxacin

- for acute bacterial rhinosinusitis, 9:109, 110, 10:121
- for community-acquired pneumonia, 16:193t, 194t

GBS. *See* Guillain-Barré syndrome

Gemifloxacin, 10:116

Gender differences

- in pediatric foreign body ingestion, 3:30
- in stroke, 5:57, 64

Genitalia, necrotizing gangrene of, 14:172t, 173-174

Gentamicin (Garamycin)

- for acute cholecystitis, 23:284
- for necrotizing enterocolitis, 22:274
- for volvulus, 22:275

Geriatric patients. *See* Older patients

Gestational hypertension, 24:294, 295t

Glass, 4:47

Globe injuries, 18:221

Globe trauma, 18:223

Glomerulonephritis, 21:264

Glucagon, 3:34-35

Glucose, fingerstick, 6:70-71

Glycoprotein IIb/IIIa inhibitors

- with primary PCI, 8:95-96
- for ST-elevation MI, 7:85, 8:92t, 95-96, 96

Gram-negative bacteria

- in acute bacterial rhinosinusitis, 9:105, 109-110, 110t, 10:115, 121t
- in human bites, 14:168
- risk factors for, 13:151t
- in skin and soft-tissue infections, 13:150

Gram-positive bacteria, 13:150

Great Pandemic of 1918, 26:321

Group A beta-hemolytic streptococcus

- in cellulitis, 13:153t, 154
- in necrotizing fasciitis, 14:169, 170t
- in pharyngitis, 21:263-264, 266t
- in skin and soft-tissue infections, 13:150, 153

Group A streptococcus, 14:170-173

Group B streptococcus

- in cellulitis, 13:153t, 154, 155
- risk factors for, 13:151t

Group C streptococcus

- in cellulitis, 13:153t, 154, 155
- in pharyngitis, 21:263, 265t

Group G streptococcus

- in cellulitis, 13:153t, 154, 155
- in pharyngitis, 21:263, 265t

Guaifenesin

- for acute bacterial rhinosinusitis, 9:103t, 10:119t
- for upper respiratory tract infections and sinusitis, 9:108t, 10:118t

Guillain-Barré syndrome, 26:327

GUSTO V, 7:85

H

Haemophilus, 14:168t

Haemophilus influenzae

- in acute bacterial rhinosinusitis, 9:107, 10:115
- antibiotic therapy for, 10:115
- in cellulitis, 13:153t, 154, 155
- in community-acquired pneumonia, 16:189, 192, 193
- in influenza, 15:183, 26:323
- in laryngitis, 21:267
- in otitis media, 20:248, 249
- in sialadenitis, 20:255
- in sinusitis, 20:256
- in uvulitis, 21:266-267

Haemophilus influenzae type B vaccine, 21:267

Haemophilus parainfluenzae, 21:267

Hampton's hump, 11:130, 131f

Hand, clumsy, 5:65

Hawaii, 25:318

Headache, migraine, 5:59, 20:251t

Health Canada, 15:182

Hearing loss

- acute, 20:251-252
- causes of, 20:252t
- in syndromes associated with vertigo, 20:251t

Heart failure

- congestive, 1:5-7, 11:127
- in transplant patients, 2:19, 19t

Heart transplant, 2:19-20

- contraindications to, 2:19, 20t
- etiology of heart failure in, 2:19, 19t
- indications for admission of patients, 2:20, 20t

HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, 23:288, 24:302-304

- blood pressure control in, 24:295-298
- classification of, 24:302
- clinical presentation of, 24:303
- differential diagnosis of, 24:300t, 303
- ED evaluation of, 24:303
- ED management pitfalls, 24:303t
- management of, 24:303-304

Hematoma

- perichondral, 19:236
- retrobulbar, 18:223-224
- septal, 18:226-227

Hemin (Pan-hematin), 23:289

Hemiparesis

- ataxic, 5:65
- pure motor, 5:65

Hemiplegia, functional, 5:60

Hemolytic-uremic syndrome, 22:277

Hemoptysis, 11:127, 128t

Hemorrhage

- facial trauma, 17:204
- stroke mimic, 5:58-59

Hemostasis

- facial wounds, 17:211
- ischemic stroke, 5:62

Henoch-Schonlein purpura, 22:277

Heparin

- contraindications to, 12:141t
- for ischemic stroke, 6:74-75
- low-molecular-weight, 6:74-75, 7:85, 12:139-141, 140t, 141t, 144, 144t
- for pulmonary embolism, 12:139-141
- for pulmonary embolism prophylaxis, 12:144
- for ST-elevation MI, 7:85
- unfractionated, 6:74-75, 7:85, 8:92t, 96t, 12:139-141, 140t, 144, 144t

Heredity, 5:64

Hernias, 22:276

Herpangina, 21:264t

Herpes simplex virus

- clinical presentation, diagnostic tests, and treatment of, 21:264t
- in organ transplant recipients, 2:15

HEs. *See* High-order explosives

Hexadrol. *See* Dexamethasone

HF. *See* Heart failure

High-order explosives, 4:42-43

Hirschsprung's disease, 22:277

Hispanics

- ischemic stroke in, 5:57
- risk of stroke in, 5:62
- stroke in, 5:64

Histoplasma capsulatum, 21:263

History

- epidemics of influenza, 26:321
- of severe acute respiratory syndrome, 15:177-179

HIV/AIDS

- acute abdominal pain in, 23:286-287
- clinical presentation, diagnostic tests, and treatment of, 21:264t

HMG-CoA reductase inhibitors, 5:62

Hognose, 20:250

Homatropine (Isopto Homatropine), 18:223

Homolateral ataxia, 5:65

Hong Kong, 15:178, 182

Horizontal deep stitches, 17:212, 213f

Hospitals, religious affiliated, 25:315-317

Hot tub folliculitis, 13:152

HPS. *See* Hypertrophic pyloric stenosis

HSP. *See* Henoch-Schonlein purpura

Human bites

- diagnosis and treatment of, 14:168

facial wound repair, 17:207
infectious organisms in, 14:168t
risk stratification, 14:164
treatment of, 14:169

Human information processing, S04180:4-5

HUS. *See* Hemolytic-uremic syndrome

Hydralazine (Apresoline), 24:297, 297t, 298

Hydrea (hydroxyurea), 23:286

Hydrocortisone (Cortef, Solu-Cortef), 23:289

Hydrometrocolpos, 22:278

Hydroxyurea (Hydrea, Droxia), 23:286

Hyperbaric oxygen therapy, 14:172

Hypercholesterolemia, 5:61

Hyperglycemia

and abdominal pain, 23:289
stroke mimic, 5:59-60

Hyperlipidemia, 5:62

Hypertension

chronic, 24:295t
differential diagnosis of, 24:300t, 301
gestational, 24:294, 295t
and ischemic stroke, 5:61
management of, in pregnancy, 24:295, 296f
pregnancy-induced, 24:293-294
pregnancy-related, 24:297t, 298
with superimposed preeclampsia, 24:299-300
transient, of pregnancy, 24:295t

Hypertensive disorders of pregnancy, 24:293-304

definition of, 24:295t
differential diagnosis of, 24:300t, 301

Hypertensive encephalopathy, 5:60

Hypertrophic pyloric stenosis, 22:275

Hypoglycemia, 5:59

Hyponatremia, 5:59

Hypotension, 4:50

Hypoxemic respiratory failure, acute, 1:7

I

Ibuprofen (Advil, Motrin)

for pharyngitis, 21:264t
for upper respiratory tract infections and sinusitis,
9:108t, 10:118t

IE. *See* Infectious endocarditis

Iguana bites, 14:167-168

Illicit drug use, 5:62

Imaging

of bacterial rhinosinusitis, 10:117-119
in ischemic stroke, 6:71-72

Imipenem

for community-acquired pneumonia, 16:193t, 194t
for necrotizing fasciitis, 14:172t

Immunity to influenza, 26:323

Immunocompromised patients, 23:286-287

Immunofluorescence DFA antibody staining,
26:324

Immunoglobulin, intravenous, 14:172-173

Immunosuppressive drugs, 2:15-16

Impedance plethysmography, 11:133

Impetigo contagiosa, 13:153

Impetigo, ulcerative, 13:153

Imuran. *See* Azathioprine

Inderal (propranolol), 24:298

Infections. *See also* specific organisms

bacterial, 2:18, 13:149-150, 14:162

CDC group DF-2, 14:165

CDC Nonoxidizer 1 group (NO-1), 14:165

CNS, 2:16-17

deep neck, 21:268-270

diabetic foot ulcer, 14:162-163, 163-164

distal fingers and toes, 13:156

ear, 20:246-249

in heart transplant recipients, 2:19

influenza, 26:323

in liver transplant recipients, 2:20-21

mammalian bites, 14:167-168

nosocomial, 26:323

in renal transplant recipients, 2:18

in SARS, 15:181

skin and soft-tissue, 13:149-150, 150-152, 14:162

skin appendices, 13:152-153

in transplant patients, 2:14, 16t

upper respiratory tract, 9:108t, 10:118t

urinary tract, 2:18

wound, 19:239

Infectious Disease Society of America (IDSA)

antibiotic treatment guidelines, 16:190

guidelines for antibiotic use in sinusitis, 10:119

practice guidelines for bacterial respiratory tract
infections, 10:120t

Practice Update Guidelines, 9:105

Practice Update Guidelines for community-acquired
pneumonia, 9:109-110, 109t, 10:120t

Infectious endocarditis, 14:167-168

Infectious epiglottitis, acute, 21:267

Infectious mononucleosis, 21:264t

Inferior vena caval filters, 12:143

Inflammatory bowel disease, 22:278

Influenza, 15:177, 183-186, 26:321, 329-330

antiviral medications for, 26:324, 325t, 326t

clinical features of, 26:323

clinical presentation of, 21:264t

complications of, 15:183, 184t, 26:323

diagnosis of, 15:183

diagnostic tests, 21:264t, 26:323-324

differential diagnosis of, 26:324

disease, 26:321-323

disease course, 26:323

drug prophylaxis for, 15:184, 185t

drug treatment of, 15:184-186, 185t

epidemics, 15:183, 26:321, 322, 323

epidemiology of, 26:321-322

geographic distribution of, 26:322

host factors, 26:322-323

immunity to, 26:323

incidence of, 26:321-322

management of, 26:324

mechanism and route of transmission, 26:323

mechanism of disease process, 26:323

nosocomial infections, 26:323

pandemics, 15:183, 26:321, 329

pathophysiology of, 26:323

prevalence of, 26:321-322

prevention of, 15:186, 26:324

symptomatic management of, 26:324

symptoms of, 15:183

temporal distribution of, 26:322

treatment of, 21:264t

U.S. pandemic plan, 26:329

from vaccine, 26:328

Influenza A, 21:264t, 26:323

Influenza B, 21:264t, 26:321, 323

Influenza C, 26:321, 323

Influenza centers, 15:186

Influenza Surveillance Network (WHO), 26:329

Influenza vaccine, 15:183-184, 26:324-329

adverse reactions, 26:325-327, 327

composition of, 26:327

contraindications to, 26:328

dose, 26:325, 327

efficacy, 26:325, 327

inactivated, 26:324-327

indications for, 15:183-184, 184t, 26:328

influenza from, 26:328

live attenuated, 26:327

live intranasal, 26:328

new recommendations for pediatric patients, 26:328

role of ED in vaccination, 26:329

2004 shortage, 26:328-329

timing of vaccination, 26:327-328

trivalent inactivated vaccine (TIV), 26:324

types of, 26:324-327

Influenza virus vaccine live (Flumist), 15:184

Influenza viruses, 26:323

Information processing, S04180:4-5

Informed consent, 15:182

Injury

auditory, 4:49t, 50, 50t

blast, 4:41-53

brain, 4:47

canalicular, 18:221

cardiac, 4:47

cardiovascular, 4:49t, 50t

cranial nerve, 17:205

C-spine, 17:205

deep structure, 18:219, 226, 227-228, 19:237

ear, 19:237

explosion-related, 4:49, 49t, 50t, 52f

extremity, 4:50t

eye, 4:47-48, 48f

facial, 17:201-202, 202-205, 18:219

facial nerve, 18:228-229

fragment, 4:47, 48f, 53

globe, 18:221

lacrimal duct/canalicular, 18:221

life-threatening, 17:202-205, 203t

midface, 18:227-228

nasal, 18:226

ocular, 4:49t, 50t

parotid gland/duct, 18:228

projectile, 4:47-48, 47f
renal, 4:50t

Inner ear disorders, 20:251

Inspiratory positive airway pressure, 1:2

Institute for Clinical Systems Improvement, 10:119

Institute of Medicine (IOM)
definition of quality health care, S04180:3
To Err is Human, S04180:1

Integrilin (eptifibatide), 7:85

Intermittent pneumatic compression, 12:144t

Internal jugular thrombosis, 21:270

International Stroke Trial (IST), 6:74

Intraocular/orbital foreign bodies, 18:223

Intrauterine device, 25:318

Intravenous immunoglobulin, 14:172-173

Intubation
endotracheal, 1:1
with facial burns, 17:204-205
failed, 17:203-204

Intussusception, 22:275-276

IOM. *See* Institute of Medicine

IPAP. *See* Inspiratory positive airway pressure

Ipecac, 3:31

Ipratropium, 9:103t, 10:119t

Ipsilateral amaurosis fugax, 5:64

Irrigation of facial wounds, 17:210-211

Ischemia, mesenteric, 23:285-286

Ischemic stroke syndromes, 5:57-65, 6:69-75
definitions, 5:57-58
differential diagnosis of, 5:58, 59t
disposition, 6:75
diurnal and seasonal variations, 5:60-61
early management guidelines, 6:73
ED management of, 6:72-73
general physical examination, 6:70
hemostatic factors, 5:62
history, 6:69-70
imaging, 6:71-72
laboratory investigations, 6:70-71
neurologic examination, 6:70
pathophysiology, 5:58
prevention of, 5:61-64
risk factors for, 5:61-64, 61t
treatment of, 6:72-75

Islet transplantation, clinical, 2:22

Isoptin (verapamil), 24:297t

Isopto Homatropine (homatropine), 18:223

IST. *See* International Stroke Trial

Itraconazole (Sporanox)
for malignant otitis externa, 20:247
for pharyngitis, 21:265t

IUD (intrauterine device), 25:318

J

JNC-7. *See* Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure

Job's syndrome, 13:154

Joint Commission on Accreditation of Healthcare Organizations (JCAHO) Core Measures initiative, S04180:6

Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7) recommended blood pressure limits, 5:61

Judgment
heuristics and limitations, S04180:4, 5t
mechanics of, S04180:4

K

Keflex. *See* Cephalexin

Ketamine (Ketalar)
for facial wound repair sedation, 17:209
for pediatric patients, 19:241

Ketolides, 16:192-195

Kidrolase (L-asparaginase), 23:286

Kim, Daniel, 9:102, 10:121

Klebsiella, 13:152

Klebsiella pneumoniae
in necrotizing fasciitis, 14:169, 170t
risk factors for, 13:151t
in sialadenitis, 20:255

L

Labeling, S04180:5t

Labetalol (Normodyne, Trandate)
for abdominal aortic aneurysm, 23:285
and ischemic stroke, 6:73
usage in pregnancy, 24:295, 297-298, 297t

Labor, preterm, 23:288

Labyrinthitis
acute, 20:251
hearing status in, 20:251t

Lacerations
chin, 19:233
ear, 19:236-237, 236f
eyebrow and eyelid, 18:219-220
facial wound repair, 17:207-208
lip, 19:237-238, 237f
mucosal, 19:238
tongue, 19:238
wound management, 4:53

Lacrimal duct/canalicular injuries, 18:221

Lacunar syndromes, 5:65

Large bowel obstruction, 23:282

Laryngeal mask airway, 17:203-204

Laryngitis, 21:267

L-asparaginase (Elspar, Kidrolase), 23:286

Lateral canthotomy, 18:223-224, 224f

Latex agglutination, 11:129

Lead toxicity, 23:289

Leaving without treatment, S04180:2

LeFort fractures, 18:229-230, 229f

Leg swelling, 11:128, 128t

Legionella pneumoniae
in community-acquired pneumonia, 16:189, 192, 193

testing for, 16:195

Lessina, 25:312t

LET (lidocaine/epinephrine/tetracaine), 17:209

Levlen, 25:312t

LevLite, 25:312t

Levofloxacin
for acute bacterial rhinosinusitis, 9:109, 109t, 110, 110t, 10:115, 116, 120t, 121, 121t
for community-acquired pneumonia, 16:193t, 194t-195t
for human and mammalian bites, 14:167t
resistance to, 9:105

Levonorgestrel
for emergency contraception, 25:310-311, 311, 313
oral EC options, 25:311, 312t
side effects of, 25:313-314, 314

Levora, 25:312t

Lidocaine (Xylocaine)
chemical classification of, 17:209, 209t
for epistaxis, 20:253t
for facial wound repair anesthesia, 17:208-209
for facial wound repair sedation, 17:209
for mandible dislocation reduction, 19:235
for nasal foreign bodies, 20:254
for tongue and mucosal lacerations, 19:238

Life-threatening facial injury, 17:202-205, 203t

Linezolid, 16:194t-195t

Lip laceration repair, 19:237-238, 237f

Lisinopril (Zestril, Prinivil), 24:297t

Liver, acute fatty, 24:300

Liver transplant, 2:20-22
contraindications to, 2:20, 21t
diagnoses in patients requiring, 2:20, 21t
ED evaluation, 2:22
indications for admission of patients, 2:22, 22t
infectious complications, 2:20-21
postoperative complications, 2:21
procedure, 2:20

LMA. *See* Laryngeal mask airway

LMWH. *See* Low-molecular-weight heparin

Local anesthetics, 17:209, 209t

Loop diuretics, 24:297t

Lo/Ovral, 25:312t

Lopressor (metoprolol)
for ST-elevation MI, 8:92t, 96t
usage in pregnancy, 24:298

Loracarbef (Lorabid)
for acute bacterial rhinosinusitis, 9:109t, 110t, 10:120t, 121t
for acute otitis media, 20:250t

Loratadine, 9:108t, 10:118t

Lorazepam, 20:251t

Losartan (Cozaar)
for prevention of stroke, 5:62
usage in pregnancy, 24:297t

Lotrimin. *See* Clotrimazole

Lower face nerve blocks, 17:210

Low-molecular-weight heparin
advantages and disadvantages of, 12:140t
for deep vein thrombosis, 12:140, 141t

for DVT and PE prevention, 12:144, 144t

for ischemic stroke, 6:74-75

for pulmonary embolism, 12:139-141

for ST-elevation MI, 7:85

Low-Ogestrel, 25:312t

Low-order explosives, 4:43-44

Ludwig's angina, 21:270

Lung damage

in blast injuries, 4:45-46, 50

precautions, 4:53

Lung scanning, 11:132

LWOT. *See* Leaving without treatment

LWs. *See* Low-order explosives

Lymphatic complications, post-surgical, 2:17

M

Macrolides

for acute bacterial rhinosinusitis, 9:107, 109t

for acute otitis media, 20:250t

for community-acquired pneumonia, 16:192, 193t, 194t-195t

for erythrasma, 13:153

regimens for GABHS pharyngitis, 21:266t

short-course therapy, 10:114

Magnesium sulfate

antidote to, 24:298t

contraindications to, 24:302

dosage regimens for preeclampsia and eclampsia, 24:298t, 302

for eclampsia, 24:302

for HELLP syndrome, 24:304

for hypertension in pregnancy, 24:296f, 297-298

monitoring, 24:298t, 302

Magnesium toxicity, 24:301t, 302

Magnetic resonance cholangiopancreatography, 23:284

Magnetic resonance imaging

in ischemic stroke, 6:72

in sinusitis, 10:117-119

Malignant otitis externa, 20:247

Mammalian bites, 14:164-169

anatomical location of, 14:164

bacteriology of, 14:164, 164t

high-risk wounds, 14:164, 164t

infectious organisms in, 14:164, 164t

puncture wounds, 14:164

rare infections related to, 14:167-168

risk stratification, 14:164

wound complications, 14:164, 164t

wound depth, 14:164

Mandible dislocation, 19:235, 236f

Mandible fractures, 19:233-234

pediatric, 19:241

sites and frequency of, 19:233-234, 235f

Mandible trauma, 19:233-235

Marcaine (bupivacaine), 17:209

Mastoiditis, 20:249

Maxillary or LeFort fractures, 18:229-230

Maxillary sinus fractures, 18:230

Mechanical reperfusion, 8:90-97

Meckel's diverticulum, 22:277-278

Meclizine (Antivert, Bonine)

for nausea after EC, 25:314, 314t

for vestibular neuronitis, 20:251, 251t

Medical errors

definition of, S04180:3, 3t

in emergency medicine, S04180:2-3

To Err is Human (IOM), S04180:1

glossary, S04180:3t

recommended actions for reduction of, S04180:5-6

scope and nature of, S04180:2-3

systems approach to reduction of, S04180:3

types of, S04180:4t

Medications

antiviral, 26:324, 325t, 326t

drug interactions with emergency contraception, 25:313

for foreign body ingestion, 3:34-35

immunosuppressive drugs, 2:15-16

for influenza prophylaxis, 15:184, 185t

for influenza treatment, 15:184-186, 185t

for stroke prevention, 5:62-64

MedImmune, 26:328, 329

Mediterranean fever, familial, 23:289

Mefoxin. *See* Cefoxitin

Meniere's disease, 20:251, 251t

Meningitis, 5:60

Mepivacaine (Carbacaine)

chemical classification of, 17:209, 209t

for facial wound repair anesthesia, 17:209

Meropenem

for community-acquired pneumonia, 16:193t, 194t

for necrotizing fasciitis, 14:172t

Mesenteric adenitis, 22:277

Mesenteric ischemia, 23:285-286

Metabolic acidosis, 2:23

Metal detectors, 3:33

Methicillin-resistant *Staphylococcus aureus*

community-acquired, 13:150-151, 14:163

risk factors for, 13:151t

in skin and soft-tissue infections, 13:150-151

Methyldopa (Aldomet), 24:295, 297t, 298

Metoprolol (Lopressor, Toprol), 24:298

Metronidazole (Flagyl, Triacide, Florazole-ER)

for acute cholecystitis, 23:284

for necrotizing fasciitis, 14:172t

for peritonsillar abscess, 21:266

for sialadenitis, 20:256

for volvulus, 22:275

Mexicans, 23:282-283

Midazolam (Versed)

for facial wound repair sedation, 17:209

for mandible dislocation reduction, 19:235

for pediatric patients, 19:240-241

Middle cerebral artery syndrome, 5:64

Midface nerve blocks, 17:209-210

Midface trauma, 18:227-230

deep structure injury, 18:227-228

fractures, 18:229-230

Mifepristone (RU486), 25:318

Migraine headache

hearing status in, 20:251t

stroke mimic, 5:59

Milroy's disease, 13:154

Mirizzi's syndrome, 23:283

Miscarriage, 23:288

MITI Trial. *See* Myocardial Infarction Triage and Intervention Trial

MMF. *See* Mycophenolate mofetil

Moraxella catarrhalis

in acute bacterial rhinosinusitis, 9:107, 10:115

antibiotic therapy for, 10:115

in community-acquired pneumonia, 16:189, 192, 193

in deep neck infections, 21:269

in epiglottitis, 21:267

in laryngitis, 21:267

in otitis media, 20:248, 249

in sinusitis, 20:256

Morning-after-pill, 25:309, 310

Morphine sulfate, 8:92t, 96t

Mosher, Steven, 9:102, 10:121

Motor hemiparesis, 5:65

Motrin. *See* Ibuprofen

Moxifloxacin

for acute bacterial rhinosinusitis, 9:109, 109t, 110, 110t, 10:116, 120t, 121, 121t

for community-acquired pneumonia, 16:193t, 194t-195t

for diabetic foot ulcer infections, 14:163

for human and mammalian bites, 14:167t

MRI. *See* Magnetic resonance imaging

MRSA. *See* Methicillin-resistant *Staphylococcus aureus*

Mucosal lacerations, 19:238

Mucous-thinning agents, 9:107, 108t, 10:118t, 119t

Multiple sclerosis

hearing status in, 20:251t

stroke mimic, 5:60

Murphy's sign, 23:284

Alfred P. Murrah Federal Building (Oklahoma City) bombing, 4:41, 45

Mycobacterium fortuitum, 13:152

Mycobacterium marinum

in cellulitis, 13:153t, 154

risk factors for, 13:151t

Mycobacterium tuberculosis, 21:267

Mycophenolate mofetil, 2:15-16

Mycoplasma, 21:263

Mycoplasma pneumoniae

in community-acquired pneumonia, 16:189, 192, 193

differential diagnosis of, 26:324

in pharyngitis, 21:265t

Mycostatin (nystatin), 21:265t

Myocardial infarction

acute, 7:81, 8:89-90, 91-94, 96, 97

ST-elevation, 7:82, 83-85, 8:89-97, 92t-93t, 96t

Myocardial Infarction Triage and Intervention (MITI) Trial, 7:84

Myringitis, bullous, 20:249

N

N95 masks, 15:177, 181
Nadroparin, 12:141t
Naproxen, 9:108t, 10:118t
Narcotics, 9:108t, 10:118t
Nasal congestion
differential diagnosis of, 9:105t
treatment options, 9:108t, 10:118t
Nasal foreign bodies, 20:254-255
Nasal fractures, 18:226
Nasal saline spray, 9:108t, 10:118t
Nasal steroids, 9:103t, 107, 10:119t
Nasal trauma, 18:225-227
National Ambulatory Medical Care Survey, 9:101
National Cholesterol Education Program, 5:62
National Committee on Clinical Laboratory Standards (NCCLS), 16:191
National Conference of Catholic Bishops, 25:317
National Institute of Neurological Disorders and Stroke (NINDS), 6:73-74
National Institutes of Health Stroke Scale (NIHSS), 6:70, 71t
National Sexual Violence Resource Center (NSVRC), 25:311
Native Americans
cholelithiasis in, 23:282-283
necrotizing fasciitis in, 14:169
Nausea and vomiting, 25:314, 314t
NebuPent (pentamidine), 23:286
NEC. *See* Necrotizing enterocolitis
Necrotizing enterocolitis, 22:274
Necrotizing fasciitis, 14:169-173
antimicrobial agents in treatment of, 14:172t
of genitalia, 14:173-174
pathologic organisms in, 14:170t
perineal, 14:173-174
type 1, 14:171, 172t
type 2, 14:172, 172t
Needle aspiration, 21:266
Neglect
of base rates, S04180:5t
elder, 23:286
Neisseria gonorrhoeae, 21:263, 265t
Neisseria meningitidis, 21:263
Nephropathy, chronic allograft, 2:18
Nerve blocks, facial, 17:209-210
Neurologic system
complications in solid organ transplant patients, 2:16-17
explosion-related injuries, 4:49t, 50t
Neuromuscular diseases, chronic and acute, 1:8
Neurontin (gabapentin), 23:289
Neuroprotectants, 6:75
New Mexico, 25:318
NF. *See* Necrotizing fasciitis
Nicardipine, 6:73
Nifedipine (Procardia, Adalat)
and ischemic stroke, 6:73
usage in pregnancy, 24:295, 297t

NIHSS. *See* National Institutes of Health Stroke Scale
NINDS. *See* National Institute of Neurological Disorders and Stroke
Nitrates, 8:92t
Nitroglycerin, 8:92t, 96t
Nitroprusside, 6:73
NIV. *See* Noninvasive ventilation
Noninvasive ventilation, 1:1-8
algorithm for, 1:6f
basics of, 1:2-4
complications of, 1:4
contraindications to, 1:3, 3t
criteria for termination, 1:4, 5t
discontinuation of, 1:4
evidence for, 1:4-8
indications for, 1:3
initiation of therapy, 1:3-4
modalities of, 1:2-3
monitoring parameters, 1:4, 4t
pathophysiology of, 1:2
patient interfaces, 1:3
patient selection for, 1:3
in prehospital setting, 1:8
resource utilization, 1:4
Nonoxidizer 1 group (NO-1), 14:165
Nordette, 25:312t
Norgestrel, 25:311
Normodyne. *See* Labetalol
Nose disorders, 20:252-257
Nosocomial infections, 26:323
NSVRC. *See* National Sexual Violence Resource Center
Nutritional support, 14:173
Nystatin (Mycostatin), 21:265t

O

Obesity, 11:127
Ocular injuries, explosion-related, 4:49t, 50t
OE. *See* Otitis externa
Ofloxacin (Floxin)
for otitis externa, 20:247, 248t
for pharyngitis, 21:265t
Oklahoma City bombing, 4:41, 45
OKT3, 2:16
Older patients
acute abdominal pain in, 23:281-286
elder abuse and neglect, 23:286
1996 Olympics bombing, 4:41
OM. *See* Otitis media
Omicef. *See* Cefdinir
Omnipen. *See* Ampicillin
Open globe injury, 18:221
Oral emergency contraception, 25:311, 312t
Oral trauma, 19:237-239
Orbital cellulitis, 13:155
Orbital foreign bodies, 18:223
Orbital fractures, 18:224-225
pediatric, 19:241
Orbital trauma, 18:219-225

Organ donation
contraindications to, 2:15t
myths, 2:13, 15t
Organ procurement, 2:13-14
Organ transplant recipients
diagnostic evaluation of, 2:24
disposition, 2:24
general evaluation of, 2:24
immunosuppressive drugs for, 2:15-16
neurologic complications in, 2:16-17
targeted physical exam of, 2:23t
Organ transplantation
evaluation and management of patients, 2:13-24
myths, 2:13, 15t
Oseltamavir (Tamiflu)
for influenza, 15:185t, 186, 26:324
precautions and toxicity, 26:325t
recommended daily dosage, 26:326t
Osteomyelitis, 14:168f
Otalgia, 20:246
referred, 20:251
OTC emergency contraception, 25:317-318
Otitis externa, 20:246-247
precipitants, 20:248t
Otitis media
AAP and AAFP recommendations for, 20:249, 250t
acute, 20:248, 249, 250t
antibiotics approved for, 20:250t
chronic suppurative, 20:249
complications of, 20:249
diagnosis of, 20:248
with effusion, 20:248
epidemiology of, 20:247-248
pathophysiology, 20:248
physical examination of, 20:248
risk factors for, 20:248, 249t
treatment of, 20:248-249
Otolaryngologist, 9:105-106
referral triggers, 9:106t
Ototoxicity, 20:251t
Outpatient treatment of pulmonary embolism, 12:140-141
Ovarian torsion, 22:278
Over-the-counter emergency contraception, 25:317-318
Ovulation Approach, 25:317
Oxygen therapy, hyperbaric, 14:172
Oxymetazoline
for epistaxis, 20:253t
for upper respiratory tract infections and sinusitis, 9:108t, 10:118t

P

Pain
abdominal, 23:288-289
acute abdominal, 22:273-278, 275t, 23:281-289, 283t
chest, 11:127, 128t
ear, 20:246, 247t

<p>Ludwig's angina, 21:270</p> <p>Pancreas transplant, 2:22-24 complications, 2:22-23 contraindications to, 2:22, 22t ED evaluation, 2:23-24 epidemiology of, 2:22 procedure, 2:22</p> <p>Pancreatic islet transplantation, clinical, 2:22</p> <p>Pancreatitis pancreas transplant, 2:23 in pediatric patients, 22:278 in pregnant patients, 23:287 risk factors for, 23:286</p> <p>Pandemics influenza, 15:183, 26:321, 329 preparing for, 15:186 U.S. influenza plan, 26:329</p> <p>Panfacial fractures, 18:229</p> <p>Pan-hematin (hemin), 23:289</p> <p>Papadakis, Aphrodite, 9:102, 10:121</p> <p>Papain, 3:34</p> <p><i>Paracoccidioides brasiliensis</i>, 21:263</p> <p>Paralysis Bell's palsy, 5:59 Todd's paralysis, 5:59</p> <p>Parapharyngeal abscess, 21:268</p> <p>Parents, 19:239-240</p> <p>Paronychia, 13:156</p> <p>Parotid gland, 18:227, 227f, 228</p> <p>Parotid gland/duct injury, 18:228</p> <p>Partial thromboplastin time, 12:139</p> <p><i>Pasteurella multocida</i> in cat bites, 14:166 in cellulitis, 13:153t, 154 in dog bites, 14:165 in human and mammalian bites, 14:167t in mammalian bite wounds, 14:164, 164t risk factors for, 13:151t</p> <p>PATCAR. <i>See</i> Prehospital Administration of Thrombolytic Therapy with Urgent Culprit Artery Revascularization</p> <p>Patient safety, S04180:3t</p> <p>PCI. <i>See</i> Percutaneous coronary intervention</p> <p>PCR. <i>See</i> Polymerase chain reaction</p> <p>PDSA model. <i>See</i> Plan-Do-Study-Act model</p> <p>PE. <i>See</i> Pulmonary embolism</p> <p>Pediapred. <i>See</i> Prednisone</p> <p>Pediatric patients acute abdominal pain in, 22:274-278, 23:286 bite wounds, 19:239 esophageal foreign body ingestion, 3:29-37, 32f facial fractures, 19:241 facial trauma, 19:239-241 new recommendations for influenza vaccination, 26:328 restraints and sedation of, 19:240-241 sinusitis, 10:119</p> <p>Pediazole (erythromycin/sulfisoxazole), 20:250t</p> <p>Pediotic, 20:248t</p> <p>Penicillin</p>	<p>for acute otitis media, 20:250t</p> <p>for human and mammalian bites, 14:167t</p> <p>for necrotizing fasciitis, 14:172t</p> <p>regimens for GABHS pharyngitis, 21:266t</p> <p>resistance to, 20:249</p> <p>Penicillin G for mandible fracture, 19:234-235 regimens for GABHS pharyngitis, 21:266t</p> <p>Pennsylvania, 25:317</p> <p>"Penny pincher," 3:34</p> <p>Pentacarinat (pentamidine), 23:286</p> <p>Pentam (pentamidine), 23:286</p> <p>Pentamidine (Pentam, NebuPent, Pentacarinat), 23:286</p> <p>Peoria Protocol, 25:317</p> <p>Peptic ulcer disease, 23:286</p> <p>Peptostreptococcus in necrotizing fasciitis, 14:169, 170t in peritonsillar abscess, 21:265 in pharyngitis, 21:263</p> <p>Percutaneous coronary intervention for acute MI, 8:89-90, 91 combined with GPIIb/IIIa inhibitors, 8:95-96 facilitated, 8:96-97 for ST-elevation MI, 8:89-96, 93t, 95t transfer for, 8:94-95 without cardiac surgery back-up, 8:91-94</p> <p>Percutaneous transluminal coronary angioplasty, 8:90</p> <p>Perfusion-weighted imaging, 6:72</p> <p>Perianal cellulitis, 13:155</p> <p>Perineal necrotizing fasciitis, 14:172t, 173-174</p> <p>Periorbital cellulitis, 13:155</p> <p>Peritonsillar abscess, 21:264-266</p> <p>Pharmacologic reperfusion, 7:83-85, 8:92t</p> <p>Pharyngitis, 21:263-264 group A beta-hemolytic Streptococcus, 21:266t miscellaneous agents that cause, 21:265t viral agents that cause, 21:264t</p> <p>PhastSystem, 18:226</p> <p>Phenergan (promethazine hydrochloride), 25:314t</p> <p>Phenylephrine for epistaxis, 20:253t for upper respiratory tract infections and sinusitis, 9:108t, 10:118t</p> <p>Phenytoin (Dilantin) dosage regimens for preeclampsia and eclampsia, 24:298t, 302 for eclampsia, 24:302</p> <p>Physical examination in ischemic stroke, 6:70 in otitis media, 20:248 of transplant patient, 2:23t, 24</p> <p>Physical inactivity, 5:62</p> <p>PIH. <i>See</i> Pregnancy-induced hypertension</p> <p>Piperacillin, 16:193t, 194t</p> <p>Piperacillin/tazobactam (Zosyn, Taxocin) for acute cholecystitis, 23:284 for community-acquired pneumonia, 16:193t, 194t-195t</p>	<p>Plan-B contraindications to, 25:313 for emergency contraception, 25:311, 312t OTC status, 25:317-318</p> <p>Plan-Do-Study-Act (PDSA) rapid-cycle improvement model, S04180:6</p> <p>Planned Parenthood, 25:311, 318</p> <p>Platelet-derived growth factor gel (Becaplermin), 14:163</p> <p>Pneumococcal resistance, 20:249, 249t</p> <p>Pneumomediastinum, 4:46</p> <p>Pneumonia community-acquired, 9:109-110, 109t, 10:114, 120t, 16:189-196 with influenza, 26:323 noninvasive ventilation for, 1:8</p> <p>Pneumonia Patient Outcomes Research Team (PORT) Severity Index, 16:190, 191t-192t</p> <p>Pneumoperitoneum, 4:46</p> <p>Pneumothorax in blast injuries, 4:46 precautions, 4:53</p> <p>Polycillin. <i>See</i> Ampicillin</p> <p>Polyglactin suture (Vicryl), 17:211</p> <p>Polyglycolic acid suture (Dexon), 17:211</p> <p>Polymerase chain reaction, 26:324</p> <p>Polymyxin, 20:248t</p> <p>Polymyxin B for hot tub folliculitis, 13:152 for paronychia, 13:156</p> <p>Polyserositis, recurrent, 23:289</p> <p>Pontocaine (tetracaine) for corneal abrasions, 18:222 for facial wound repair anesthesia, 17:209</p> <p>Porphyria, 23:289</p> <p>Porphyromonas spp., 14:164t</p> <p>Portia, 25:312t</p> <p>Posterior cerebral artery syndrome, 5:64-65</p> <p>Potential adverse events, S04180:3, 3t</p> <p>Powered air-purifying respirator, 15:181</p> <p>PPA. <i>See</i> Parapharyngeal abscess</p> <p>PRAGUE trial, 8:94</p> <p>PRAGUE-2 trial, 8:94</p> <p>Pravastatin, 5:62</p> <p>Prednisone (Delta-Cortef, Prelone, Pediapred, Deltasone) for Bell's palsy, 21:262 for familial Mediterranean fever, 23:289</p> <p>Preeclampsia, 24:294, 299-300 anticonvulsant dosage regimens for, 24:298t blood pressure control in, 24:295-298, 297t classification of, 24:299 clinical presentation of, 24:299-300 definition of, 24:295t, 299 differential diagnosis of, 24:300t, 301 ED management pitfalls, 24:303t HELLP syndrome, 23:288, 24:295-298, 302-304 management of, 24:300 pathophysiology of, 24:299 prevention of, 24:300</p>
---	---	---

<p>risk factors for, 24:299t severe, 24:299, 299t signs, symptoms, and lab values associated with, 24:299t superimposed, 24:295t, 299-300</p> <p>Pregnancy acute abdominal pain in, 23:287-288 acute fatty liver of, 24:300 antihypertensive medications and usage in, 24:295-298, 297t blood pressure control in, 24:295-298 ectopic, 23:287-288, 25:314 hypertensive disorders of, 24:293-304, 295t influenza vaccine during, 26:327 management of hypertension in, 24:295, 296f prevention of, 25:309-310 transient hypertension of, 24:295t unintended, 25:309</p> <p>Pregnancy Approach, 25:317</p> <p>Pregnancy-induced hypertension, 24:293-294 antihypertensive medications and usage in, 24:297t, 298 continuum of, 24:294 definition of, 24:294</p> <p>Prehospital Administration of Thrombolytic Therapy with Urgent Culprit Artery Revascularization (PATCAR), 7:83</p> <p>Prehospital ECG transmission, 7:83-85</p> <p>Prehospital fibrinolysis, 7:83-85</p> <p>Prehospital noninvasive ventilation, 1:8</p> <p>Pressure support ventilation, 1:3</p> <p>Pressure ulcers, 13:154</p> <p>Preterm labor, 23:288</p> <p>Preven, 25:311, 312t, 313</p> <p>Preventable adverse events, S04180:3, 3t</p> <p>Prevotella in human bite wounds, 14:168t in mammalian bite wounds, 14:164t</p> <p>Principen. <i>See</i> Ampicillin</p> <p>Prinivil (lisinopril), 24:297t</p> <p>Procaine chemical classification of, 17:209, 209t for facial wound repair, 17:209</p> <p>Procardia. <i>See</i> Nifedipine</p> <p>Procedural sedation, 17:209</p> <p>Progesterin, 25:311, 312-313, 314</p> <p>Projectile injuries, 4:47-48, 47f</p> <p>Promethazine hydrochloride (Phenergan), 25:314t</p> <p>Propranolol (Inderal), 24:298</p> <p>Proteinuria, 24:300t, 301</p> <p>Proteus in chronic suppurative otitis media, 20:249 in folliculitis, 13:152</p> <p><i>Proteus mirabilis</i>, 14:169, 170t</p> <p>Pseudoephedrine, 9:108t, 10:118t</p> <p>Pseudomonas in necrotizing fasciitis, 14:169 risk factors for, 16:193t</p> <p><i>Pseudomonas aeruginosa</i> in cellulitis, 13:153t, 154, 155</p>	<p>in chronic suppurative otitis media, 20:249 in dog bites, 14:165 in folliculitis, 13:152 in necrotizing fasciitis, 14:169, 170t in otitis externa, 20:246, 247 in paronychia, 13:156 risk factors for, 13:151t in sialadenitis, 20:255 in sinusitis, 20:256 in skin and soft-tissue infections, 13:150 in skin infections, 13:153</p> <p>PSV. <i>See</i> Pressure support ventilation</p> <p>PTA. <i>See</i> Peritonsillar abscess</p> <p>PTCA. <i>See</i> Percutaneous transluminal coronary angioplasty</p> <p>Pujol, Isidro, 9:102, 10:121</p> <p>Pull-tops, 3:31</p> <p>Pulmonary angiography, 11:132</p> <p>Pulmonary barotrauma in blast injuries, 4:46, 53 precautions, 4:53</p> <p>Pulmonary contusion in blast injuries, 4:46 noninvasive ventilation for, 1:8</p> <p>Pulmonary damage in blast injuries, 4:45-46, 50 precautions, 4:53</p> <p>Pulmonary disease, chronic obstructive, 1:4-5</p> <p>Pulmonary edema, acute, 1:5-7</p> <p>Pulmonary embolism, 11:125, 133-134 in blast injuries, 4:42, 53 clinical evaluation of, 11:128-132, 133f clinical manifestations of, 11:127-128 combination strategies for evaluation of, 11:132-133 diagnosis of, 11:125, 128, 132-133, 133f differential diagnosis of, 12:137, 138, 139t ECG prediction of, 11:130, 130t ECG scoring system for pulmonary hypertension from, 11:130, 130t epidemiology of, 11:125-126 mortality rates, 11:126 outpatient treatment of, 12:140-141 pathophysiology of, 11:126-127 pretest clinical probability of, 11:133f prevention of, 12:144, 144t risk factors for, 11:127, 127t signs and symptoms of, 11:127-128, 128t, 12:138, 139t thrombolytic therapy in, 12:141-142 treatment of, 4:53 treatment options, 12:138-143 Wells' criteria for, 11:128, 129t</p> <p>Pulmonary hypertension, 11:130, 130t</p> <p>Puncture wounds, 14:164</p> <p>Pure motor hemiparesis, 5:65</p> <p>Pure sensory stroke, 5:65</p> <p>PWL. <i>See</i> Perfusion-weighted imaging</p> <p>Pyelonephritis in pediatric patients, 22:278 in pregnant patients, 23:288</p>	<p>Pyloric stenosis, hypertrophic, 22:275</p> <p>Pyoderma, 13:155</p> <p>Pyramidal fractures, 18:229, 229f</p> <p>Q</p> <p>Quality definition of, S04180:3, 3t domains of, S04180:3 indicators and assurance in community-acquired pneumonia, 16:195-196</p> <p>Quality initiatives, S04180:3-4</p> <p>Quaternary blast injuries, 4:48</p> <p>R</p> <p>Race, 5:64</p> <p>Radiographic studies in acute sinusitis, 10:119 in bacterial rhinosinusitis, 10:117-119 in blast injuries, 4:49 in pediatric foreign body ingestion, 3:32-33, 32f in pulmonary embolism, 11:130 in severe acute respiratory syndrome, 15:180</p> <p>RADTS. <i>See</i> Rapid antigen detection tests</p> <p>Rales/crackles, 11:128 in pulmonary embolism, 11:128t</p> <p>Rape, 25:309, 315, 316f</p> <p>Rapid antigen detection tests for influenza, 26:324 for pharyngitis, 21:263</p> <p>RDX (Royal Demolition eXplosive), 4:42-43</p> <p>Referred otalgia, 20:251</p> <p>Reflux, gastroesophageal, 23:288</p> <p>Regression toward the mean, S04180:5t</p> <p>Rejection heart transplant, 2:19 liver transplant, 2:21-22 pancreas transplant, 2:22-23 renal transplant, 2:17-18</p> <p>Relenza (zanamivir) for influenza, 15:185t, 186, 26:324 precautions and toxicity, 26:325t recommended daily dosage, 26:326t</p> <p>Religious affiliated hospitals, 25:315-317</p> <p>Renal colic, 22:278</p> <p>Renal injury, explosion-related, 4:50t</p> <p>Renal transplant, 2:17-19 causes of early graft dysfunction, 2:18t causes of late post-transplant graft dysfunction, 2:17t complications, 2:17</p> <p>ED evaluation, 2:18-19 infectious causes of death in recipients, 2:18, 18t most common diagnoses in patients requiring, 2:17, 17t post-surgical complications, 2:17 procedure, 2:17 rejection, 2:17-18 treatment, 2:19</p> <p>ReoPro (abciximab)</p>
---	---	--

combined with retevase, 8:97
for ST-elevation MI, 7:85, 8:92t, 95-96, 96t, 97

Reperfusion therapy

for acute MI, 7:81-88
mechanical, 8:89-97, 90-97
pharmacologic, 7:83-85

Representativeness, S04180:5t

Reproductive physiology, 25:310

Reptilian bites, non-venomous, 14:167-168

Rescue devices for difficult airway management or failed intubation, 17:203-204

Respiratory disease, acute, 15:177

Respiratory failure, acute hypoxemic, 1:7

Respiratory system

clinical signs and symptoms of significant explosion-related injuries, 4:49t
explosion-related injuries, 4:50t

Restraints, pediatric, 19:240-241

Reteplase (r-PA)

prehospital, 7:84
for ST-elevation MI, 7:83, 84, 8:96t

Retevase

dosing, 12:142t
for ST-elevation MI, 8:97

Retrobulbar hematoma, 18:223-224

Retropharyngeal abscess, 21:268-269

Reviparin

dosing for DVT with or without PE, 12:141t
for DVT prevention, 12:144
for pulmonary embolism, 12:140

Reynold's pentad, 23:283

Rheumatic fever, 21:264

Rhinitis, vasomotor, 9:103t

Rhinorrhea

CSF, 18:226-227
differential diagnosis of, 9:105t

Rhinosinusitis, acute bacterial

AAOHNS guidelines, 10:115
antibiotic selection for, 9:106-110
antibiotic therapy for, 9:101-110, 103t, 10:113-121
antimicrobial treatment issues, 9:104
definition of, 9:102-103
diagnosis of, 9:103-104
differential diagnosis of, 9:105t, 10:117
drug resistance in, 9:104-105
epidemiological patterns, 9:104-105
microbiology of, 9:107
patient evaluation in, 10:117-119
referral triggers, 9:105-106, 106t
risk factors and clinical conditions predisposing to or associated with, 9:104t
short-course therapy for, 10:113-114
signs and symptoms associated with, 9:105, 105t
treatment guidelines, 9:109t, 110t, 10:120t, 121t
Year 2004 ATBS Clinical Consensus Panel Report® and Treatment Recommendations, 9:101-110, 10:113-121

Rhinosporidium seeberi, 21:263

RhoGam (anti-D immune globulin), 23:288

Ribavirin, 15:182

Rifampin, 13:152

Rimantadine (Flumadine)

for influenza, 15:184, 185t, 26:324
precautions and toxicity, 26:325t
recommended daily dosage, 26:326t

Rinne test, 20:252

Rocephin. *See* Ceftriaxone

RPA. *See* Retropharyngeal abscess

r-PA. *See* Reteplase

RU486 (mifepristone), 25:318

Rusca, Franchino, 4:42

S

SAEM. *See* Society for Academic Emergency Medicine

Safety

culture of, S04180:5
patient, S04180:3t

Saint Francis Medical Center (Peoria, IL), 25:317

Salmonella spp., 13:151t

SARS. *See* Severe acute respiratory syndrome

SARS-associated coronavirus, 15:177

diagnostic criteria for, 15:181
disease, 15:180t

Scalp

nerve blocks for, 17:209
trauma to, 18:217-219
wound repair, 18:217-219

Scars, 17:214

Schwannoma, 20:251t

Scopolamine, 20:251t

Scratches

cat, 14:165-166
cat scratch disease, 14:166-167

Seasonal variations, 5:60-61

Seasonale, 25:312t

Secondary blast injuries, 4:42, 43f, 47-48, 47f

Sedation

for facial wound repair, 17:209
pediatric, 19:240-241

Seldinger technique, 17:203

Sensory motor stroke, 5:65

Sensory stroke, 5:65

Septal hematoma, 18:226-227

pediatric, 19:241

Sepra. *See* Trimethoprim/sulfamethoxazole (TMP-SMX)

Serratia marcescens, 14:167-168

Serum electrolytes, 6:71

Severe acute respiratory syndrome, 15:177-183

case definitions, 15:182
clinical diagnosis of, 15:179-180
criteria for admission, 15:182
definition of, 15:177-179
epidemiology of, 15:177-179
history of, 15:177-179
incubation period, 15:179-180
indications for admission for isolation, 15:182
infection control, 15:181

laboratory findings, 15:180-181

mode of transmission, 15:181

period of communicability, 15:181-182

prognosis for, 15:182

radiographic findings, 15:180

report under investigation, 15:178-179, 180t

revised case definition for, 15:178, 179t-180t

signs and symptoms of, 15:179-180

treatment of, 15:182

viral category, 15:180

Sexual assault

emergency contraception for, 25:309, 311, 315, 316f
Guidelines for Catholic Hospitals Treating Victims of Sexual Assault, 25:317

Shell-shock, 4:42

Shrapnel, 4:47, 47f

Sialadenitis, 20:255-256

Sigmoid volvulus, 23:282, 284f

Silver sulfadiazine (Silvadene), 17:212

SimpliRED exam, 11:129

Singapore

criteria for admission for SARS, 15:182
response to SARS threat, 15:181

Sinus puncture, 9:103, 10:117

Sinusitis, 20:256-257

acute bacterial, 9:101-110, 107t, 108t, 10:113-120, 118t

complications, 20:257

diagnostic evaluation of, 20:256-257

epidemiology of, 20:256

management of, 20:257

pathophysiology of, 20:256

Skin and soft-tissue infections, 13:150-152

bacterial, 13:149-150, 153-154, 14:162

bacteriology of, 13:150-151

classification of, 13:152

diagnosis of, 13:151-152

management of, 13:151-152

risk factors for specific pathogens causing, 13:151t

Skin appendices infections, 13:152-153

Skin tension lines, 17:211, 211f

Small bowel obstruction, 23:282, 283f

Society for Academic Emergency Medicine (SAEM)

position on stroke care, 6:74

recommendations for quality health care definition, S04180:3

Soft-tissue infections, 13:150-152

bacterial, 13:149-150, 14:162

risk factors for specific pathogens causing, 13:151t

Solid organ transplant patients

evaluation and management of, 2:13-24

neurologic complications in, 2:16-17

Solu-Cortef (hydrocortisone), 23:289

Spa pool folliculitis, 13:152

Spalling, 4:45

SPC. *See* Statistical process control

Speech abnormalities, 6:72t

SPEED. *See* Strategies for Patency Enhancement in the Emergency Department trial

SPEs. See *Streptococcal pyrogenic exotoxins*

Sporanox. See Itraconazole

SSTIs. See Skin and soft-tissue infections

Stander, Paul, 9:102, 10:121

Staphylococcus aureus

in acute bacterial rhinosinusitis, 9:107

in cat bites, 14:166

in cellulitis, 13:153t, 155

in chronic suppurative otitis media, 20:249

in deep neck infections, 21:269

in dog bites, 14:165

epidemics, 26:321

in felon, 13:156

in folliculitis, 13:152

in furunculosis, 13:152

in human and mammalian bites, 14:167t

in human bite wounds, 14:168, 168t

infections of skin appendices, 13:152-153

in influenza, 15:183, 26:323

in mammalian bite wounds, 14:164, 164t

methicillin-resistant, 13:150-151, 151t, 14:163

in necrotizing fasciitis, 14:169, 170t

in otitis externa, 20:246

in paronychia, 13:156

in peritonsillar abscess, 21:265

risk factors for, 13:151t

in sialadenitis, 20:255

in skin and soft-tissue infections, 13:150

in skin infections, 13:153

in wound infections, 17:213

Staples, 17:212-214

Statins

for ST-elevation MI, 8:92t

for stroke prevention, 5:62

Statistical process control, S04180:6

Status asthmaticus, 1:7

STEMI. See ST-segment elevation myocardial infarction

Stenting, coronary artery, 8:89-90

Steri Strips, 17:213

Steroids

for acute bacterial rhinosinusitis, 9:103t, 107

for Bell's palsy, 21:262

for HELLP syndrome, 24:304

immunosuppressive therapy with, 2:16

nasal, 9:103t, 107, 10:119t

Stitches, deep

horizontal, 17:212, 213f

technique for, 17:212, 212f

Stomach flu, 26:323

Strategies for Patency Enhancement in the

Emergency Department (SPEED) trial, 8:97

Streptobacillus moniliformis, 13:151t

Streptococcal pyrogenic exotoxins, 14:170

Streptococcal toxic shock syndrome, 14:170

clinical presentation of, 14:171

diagnosis of, 14:171

diagnostic criteria for, 14:171t

Streptococcus

in cat bites, 14:166

in dog bites, 14:165

group A, 14:170-173

group A beta-hemolytic, 13:150, 153, 153t, 154,

14:169, 170, 21:263-264, 266t

group B, 13:151t, 153t, 154, 155

group C, 13:153t, 154, 155, 21:263, 265t

group G, 13:153t, 154, 155, 21:263, 265t

in human bite wounds, 14:168, 168t

in mammalian bite wounds, 14:164, 164t

Streptococcus agalactiae, 13:154

Streptococcus marcescens, 14:169, 170t

Streptococcus pneumoniae

in acute bacterial rhinosinusitis, 9:105, 107, 10:115

antibiotic therapy for, 10:115

in bullous myringitis, 20:249

in cellulitis, 13:155

in community-acquired pneumonia, 16:189, 192, 193

drug-resistant, 9:105, 109-110, 110t, 10:115, 121t,

16:191-192, 20:249

in influenza, 15:183, 26:323

in otitis media, 20:248, 249

in sinusitis, 20:256, 257

testing for, 16:195

Streptococcus pyogenes

in cellulitis, 13:154, 155

in felon, 13:156

in necrotizing fasciitis, 14:169

in peritonsillar abscess, 21:265

in sialadenitis, 20:255

Streptococcus viridans

in cat bites, 14:166

in dog bites, 14:165

Streptokinase

dosing, 12:142t

for ST-elevation MI, 7:83

Stroke

acute, 6:75

definition of, 5:57-58

incidence of, 5:57

ischemic stroke syndromes, 5:57-65, 6:69-75

mimics, 5:58-60

pharmacologic agents for prevention of, 5:62-64

pure sensory, 5:65

sensory motor, 5:65

syndromes, 5:64-65, 64t

Stroke units, 6:75

ST-segment elevation myocardial infarction

ECG findings, 7:82

epidemiology of, 7:82

mechanical reperfusion of, 8:89-97

pathogenesis of, 7:82

pharmacologic reperfusion of, 7:83-85

strategies for outcome-effective management, 8:92t-93t

as trauma victims, 8:91-94

treatment options, 8:96t

STSS. See Streptococcal toxic shock syndrome

Sublimaze (fentanyl), 17:209

Succinylcholine (Anectine), 24:302

Suicide bombers, 4:41, 42

Sulfas, 20:250t

Sulfatrim. See Trimethoprim/sulfamethoxazole (TMP-SMX)

Sumycin (tetracycline), 21:265t

Superantigens, 14:170

Superimposed preeclampsia

definition of, 24:295t

hypertension with, 24:299-300

Suppurative otitis media, chronic, 20:249

Suprax. See Cefixime

Surgery, abdominal, 23:286

Sutures

absorbable, 17:211

alternatives, 17:212-214

corner, 17:212, 213f

for facial wounds, 17:211-212

forehead, 18:219, 220f

horizontal deep stitches, 17:212, 213f

technique for deep stitches, 17:212, 212f

Sweating, 11:127, 128t

Swim Ear, 20:248t

Symmetrel (amantadine)

for influenza, 15:184, 185t, 26:324

precautions and toxicity, 26:325t

recommended daily dosage, 26:326t

Syncope, 11:127

Systems approach to error reduction, S04180:3, 3t

T

TAC (tetracaine/adrenaline/cocaine), 17:209

Tachycardia, 11:127, 128t

Tachypnea, 11:127, 128t

Tacrolimus (FK 506), 2:15

Tamiflu (oseltamavir)

for influenza, 15:185t, 186, 26:324

precautions and toxicity, 26:325t

recommended daily dosage, 26:326t

Tape, 17:212-214

Tazobactam/piperacillin, 16:194t-195t

Tazocin. See Piperacillin/tazobactam

TEE. See Transesophageal echocardiography

Telithromycin, 16:192-195

Temporal arteritis, 5:60

Temporal relationships

influenza distribution, 26:322

of pediatric foreign body ingestion, 3:30

Tenecteplase (TNK)

dosing, 12:142t

for ST-elevation MI, 7:83, 85, 8:93t, 96t

Tenormin (atenolol), 24:298

Terrorism

1996 Olympics bombing, 4:41

1998 U.S. Embassy, Nairobi bombing, 4:47

2001 World Trade Center attack, 4:41, 42

blast injuries, 4:41-53

Oklahoma City bombing, 4:41, 45

suicide bombers, 4:41, 42

Tertiary blast injuries, 4:42, 43, 48

Tetanus prophylaxis, 17:208t

Tetracaine (Pontocaine)
chemical classification of, 17:209, 209t
for corneal abrasions, 18:222
for facial wound repair anesthesia, 17:209

Tetracycline (Sumycin), 21:265t

Thermal burns. See also Burns
orbital, 18:222-223

Thiazide diuretics, 24:297t

Thoracic ecchymosis, 4:46

Throat disorders, 21:263-270

Thromboembolic phenomena, 16:196

Thrombolytic therapy
absolute contraindications to, 12:142t
for acute ischemic stroke, 6:74
for acute MI, 8:89
combined with angioplasty, 8:97
contraindications to, 7:83, 83t, 8:97, 12:142t
CT indications of poor outcome after administration of, 6:71, 73t
dosing, 12:142t
immediate, 8:94-95, 95t
indications for, 7:83, 83t
for ischemic stroke, 6:73-74
prehospital, 7:84
in pulmonary embolism, 12:141-142
relative contraindications to, 12:142t
for ST-elevation MI, 7:83, 8:91, 94-95, 95t, 96t

TIAs. See Transient ischemic attacks

Ticarcillin (Ticar), 22:274

Ticarcillin/clavulanate, 16:195t

Ticlopidine, 5:63

Tigan (trimethobenzamide hydrochloride), 25:314t

Tinactin (tolnaftate), 20:247

Tinzaparin
for deep vein thrombosis, 12:140
dosing for DVT with or without PE, 12:141t
for pulmonary embolism, 12:140
for venous thromboembolism, 12:139

Tirofiban (Aggrastat), 7:85

Tissue adhesives, 17:213-214

Tissue plasminogen activator
contraindications to, 6:75t
dosing, 12:142t
indications for, 6:75t
for ischemic stroke, 6:73-74, 75t

TM. See Tympanic membrane

TMP-SMX. See Trimethoprim/sulfamethoxazole

TNK. See Tenecteplase

To Err is Human (IOM), S04180:1

Todd's paralysis, 5:59

Toes, distal, 13:156

Tolnaftate (Tinactin), 20:247

Tongue lacerations, 19:238

Tooth fractures, 19:239

Topical anesthesia, 17:209

Toprol (metoprolol), 24:298

Toxins, 23:289

Toxoplasma gondii, 21:263

tPA. See Tissue plasminogen activator

t-PA. See Alteplase

Trandate. See Labetalol

Transesophageal echocardiography, 11:130

Transfer for primary PCI, 8:94-95, 95t

Transient hypertension of pregnancy, 24:295t

Transient ischemic attacks, 5:58
disposition, 6:75
and ischemic stroke, 5:61
mimics, 5:58-60

TIA syndromes, 5:64

Transplantation
clinical islet transplantation, 2:22
general evaluation of patients, 2:24
heart transplant, 2:19-20, 19t, 20t
liver transplant, 2:20-22, 21t, 22t
myths, 2:13, 15t
pancreas transplant, 2:22-24, 22t
physical examination of patients, 2:23t, 24
problems common to all patients, 2:14-17
renal transplant, 2:17-19, 17t, 18t
solid organ transplant patients, 2:13-24

Trauma
advanced trauma life support, 17:205
dental, 19:238-239
ear, 19:235-237
facial, 17:201-202, 202-205, 203t, 18:217-230, 19:233-241
globe, 18:223
mandible, 19:233-235
midface, 18:227-230
nasal, 18:225-227
oral, 19:237-239
orbital, 18:219-225
tympanic membrane perforation, 19:237

Trikacide. See Metronidazole

Tri-Levlen, 25:312t

Trimethobenzamide hydrochloride (Tigan), 25:314t

Trimethoprim/sulfamethoxazole (TMP-SMX) (Bactrim, Septra, Sulfatrim)
for acute bacterial rhinosinusitis, 9:107
for acute otitis media, 20:250t
for diverticular disease, 23:285
for pharyngitis, 21:265t

Triphasil, 25:312t

Tripod fractures, 18:230

Trivora, 25:312t

Tymol, 13:156

Tympanic membrane perforation, 19:237

Typhlitis, 23:286-287

U

UFH. See Unfractionated heparin

Ulcerative impetigo, 13:153

Ulcers
corneal, 18:222
diabetic foot ulcer infections, 14:162-163
duodenal, 23:286
gastric, 23:286
peptic ulcer disease, 23:286

pressure, 13:154

Ultrasound
in acute rejection, 2:19t
in cholelithiasis and acute cholecystitis, 23:284
in pulmonary embolism, 11:132

Unasyn. See Ampicillin/sulbactam

Unfractionated heparin
advantages and disadvantages of, 12:140t
for DVT and PE prevention, 12:144, 144t
for ischemic stroke, 6:74-75
for pulmonary embolism, 12:139-141
for ST-elevation MI, 7:85, 8:92t, 96t

United States
epidemics of influenza in, 15:183
historical locations of bomb incidents, 4:41, 43f
pandemic influenza plan, 26:329

United States Embassy, Nairobi terrorist bombing, 4:47

United States Public Health Service, 15:183-184, 26:328

University Hospital of Maastricht (the Netherlands), 8:94

Upper extremity deep vein thrombosis
inferior vena caval filters for, 12:143
pathophysiology, 11:127

Upper respiratory tract infections
differential diagnosis of, 10:117
general management principles for, 9:108t, 10:118t
treatment options, 9:108t, 10:118t

Urgent Matters, S04180:6

Urinary tract infections
in pregnant patients, 23:288
in renal transplant recipients, 2:18

Urokinase, 12:142t

Urologic complications
of pancreas transplant, 2:23
of renal transplant, 2:17

US. See Ultrasound

UTIs. See Urinary tract infections

Uvulitis, 21:266-267

V

Vaccination
influenza, 15:183-184, 26:324-329
role of ED in, 26:329
timing of, 26:327-328

Vaginal bleeding, 25:314

Valacyclovir (Valtrex), 21:264t

Valium. See Diazepam

Valsartan (Diovan), 24:297t

Vancomycin, 16:194t-195t

Vantin. See Cefpodoxime

Varicella-zoster virus, 2:15

Vascular complications
in liver transplant recipients, 2:21
in renal transplant recipients, 2:17

Vascular thrombosis, pancreas transplant, 2:23

Vasomotor rhinitis, 9:103t, 10:119t

Vasotec (enalapril), 24:297t

Veilonella, 14:168t

Venous thromboembolism
 clinical evaluation of, 11:129
 with emergency contraception, 25:314
 epidemiology of, 11:126
 prevention of, 12:144
 risk factors for, 11:127
 treatment options, 12:139
 warfarin therapy for, 12:143

Ventilation
 bilevel positive airway pressure, 1:2
 continuous positive airway pressure, 1:2
 noninvasive, 1:1-8
 pressure support, 1:3

Ventilation-perfusion (V/Q) studies, 11:131-132

Verapamil (Isoptin, Calan, Verelan), 24:297t

Versed (midazolam)
 for facial wound repair sedation, 17:209
 for mandible dislocation reduction, 19:235

Vertebrobasilar artery syndrome, 5:65

Vertebrobasilar ischemia, 20:251t

Vertigo, 20:251, 251t

Vestibular neuronitis, 20:251, 251t

Vestibular suppressants, 20:251t

Vibramycin. *See* Doxycycline

Vibrio vulnificus
 in cellulitis, 13:153t, 154
 risk factors for, 13:151t

Vicryl (coated polyglactin suture)
 for ear lacerations, 19:236
 for facial wounds, 17:211

Videx (didanosine), 23:286

Vincent's angina, 21:265t

Viral agents, 21:264t
 testing for, 16:195

Viral cultures for influenza, 26:324

Viral prodrome, 21:264t

Viral upper respiratory tract infections
 differential diagnosis of, 10:117
 general management principles for, 9:108t, 10:118t
 treatment options, 9:108t, 10:118t

Virchow's triad, 11:127

Volturo, Gregory A., 9:102, 10:121

Volvulus
 in older patient, 23:282, 284f
 in pediatric patient, 22:274-275

Vomiting after emergency contraception, 25:314, 314t

V/Q studies. *See* Ventilation-perfusion studies

VTE. *See* Venous thromboembolism

VZV. *See* Varicella-zoster virus

W

Warfarin
 for deep vein thrombosis, 12:143
 for DVT and PE prevention, 12:144t
 for prevention of stroke, 5:63-64
 for pulmonary embolism, 12:140, 143
 for venous thromboembolism, 12:143

Washington, George, 21:267

Washington state, 25:318

Weakness, arm, 6:72t

Weber test, 20:251-252

Wells' criteria for pulmonary embolism, 11:128, 129t

Westermark's sign, 11:130

WHO. *See* World Health Organization

Women, 5:62

Women's Health Initiative, 5:62

World Health Organization (WHO)
 case definition of SARS, 15:182
 definition of stroke, 5:57-58
 global alerts, 15:177

guidelines for emergency contraception, 25:313
 influenza centers, 15:186
 Influenza Surveillance Network, 26:329

2001 World Trade Center attack, 4:41, 42

Wound glue, 17:213-214

Wound infections, 19:239

Wound management
 bites, 17:207
 in blast injuries, 4:53
 after ED, 17:214
 pediatric bites, 19:239

Wound repair
 cheek, 18:227
 chin laceration repair, 19:233
 ear laceration repair, 19:236-237, 236f
 eyebrow and eyelid, 18:219-221
 facial, 17:206-214
 forehead, 18:219
 how to make wound edges even, 17:211-212, 212f
 lip laceration repair, 19:237-238, 237f
 nasal, 18:225-227
 scalp, 18:217-219
 technique for deep stitches, 17:212, 212f

Wound tape, 17:213

X

XAP (xylocaine/adrenaline/procaine), 17:209

Xenon-enhanced CT cerebral blood flow, 6:72

X-rays. *See* Radiographic studies

Xylocaine (lidocaine)
 for facial wound repair anesthesia, 17:208-209
 for facial wound repair sedation, 17:209

Y

Year 2004 ASCAP (Antibiotic Selection for

FINANCIAL DISCLOSURE STATEMENT

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we present the following annual statement of disclosure for the editorial board members of *Emergency Medicine Reports*.

Paul S. Auerbach, MD; William Brady, MD; Kenneth Butler, DO, Michael L. Coates, MD; Alasdair K.T. Conn, MD; Paul E. Pepe, MD; David J. Robinson, MD; Barry H. Rumack, MD; Richard Salluzzo, MD; Sandra M. Schneider; David Sklar, MD; *Charles E. Stewart, MD; Steven M. Winograd, MD; and Allan B. Wolfson, MD, report no relationships with companies related to the field of study covered by this CME program.

Brooks F. Bock, MD
 Research: Faculty member, Wayne State University

Charles L. Emerman, MD
 Consultant: Scios, Sepracor
 Speaker's bureau: Scios, Pfizer, Roche, Sepracor
 Research: Scios, Separacor, Bayer

Kurt Kleinschmidt, MD
 Speaker's bureau: Aventis, Sanofi

Charles V. Pollack Jr., MD
 Consultant: Schering, Genentech, Aventis
 Speaker's bureau: Aventis, Millennium, Schering, BMS,

Roche, Pfizer
 Research: Aventis

Robert Powers, MD, MPH
 Consultant and Research: GSK
 Speaker's bureau: Ortho-McNeil

Steven G. Rothrock, MD
 Stockholder: Amgen, Gilead, Oxigene, Medtronic, Boston Scientific, Johnson & Johnson, Ivax

J. Stephan Stapczynski
 Consultant: Schering Corporation

Gregory A. Volturo, MD
 Speaker's Bureau: Aventis, Pfizer, Roche
 Research: Roche

Albert C. Wehl, MD
 Consultant: Fujisawa, Scios
 Speaker's Bureau: Fujisawa, University of Massachusetts
 CME

Gideon Bosker, MD, editor-in-chief, has been compensated for speaking engagements and/or editorial services related to production of peer-reviewed Clinical Consensus Reports® under the auspices of unrestricted educational grants for Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Roche Pharmaceuticals, Bayer, Novartis, Forest Pharmaceuticas, and Schering Plough Corporation. Dr. Bosker also acknowledges that he has received royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and/or other electronic or print materials to the following pharmaceutical companies: Pfizer, Sanofi-Aventis, Bayer, Roche, Forest Laboratories, and Novartis. He is a minor stockholder in Pfizer. Any other stock ownership which he may have in other pharmaceutical companies is managed in blinded fashion by an independent consultant without Dr. Bosker's input or consultation..

James Hubler, MD, JD; David Kramer, MD; John A. Schriver, MD, and Corey M. Slovis, MD, and Charles Stewart, MD, did not return disclosure forms.

<p>Community-Acquired Pneumonia) Consensus Panel guidelines for management of community-acquired pneumonia, 16:194t-195t</p> <p>Year 2004 ATBS (Antibiotic Therapy for Bacterial Sinusitis) Clinical Consensus Panel Report® and Treatment Recommendations, 9:101-110, 10:113-121</p> <p>Young children and parents, 19:239-240</p>	<p>Yuzpe, Albert, 25:310-311</p> <p>Z</p> <p>Zanamivir (Relenza) for influenza, 15:185t, 186, 26:324 precautions and toxicity, 26:325t recommended daily dosage, 26:326t</p> <p>Zebras, 23:288-289</p>	<p>Zestril (lisinopril), 24:297t</p> <p>Zithromax. <i>See</i> Azithromycin</p> <p>Zosyn. <i>See</i> Piperacillin/tazobactam</p> <p>Zoto HC, 20:248t</p> <p>Zovirax. <i>See</i> Acyclovir</p> <p>Zygoma fractures, 18:230</p>
--	--	--

Emergency Medicine Reports 2004 Titles

- January 2, 2004:** Noninvasive Ventilation in the Emergency Department
- January 12, 2004:** Evaluation and Management of Solid Organ Transplant Patients in the Emergency Department
- January 26, 2004:** Esophageal Foreign Bodies in the Pediatric Population: A Comprehensive Review of the Literature
- February 9, 2004:** Evaluation and Management of Patients with Blast Injuries in the ED
- February 23, 2004:** Ischemic Stroke Syndromes: The Challenges of Assessment, Prevention, and Treatment
Part I: Risk Factors, Differential Diagnosis, and Prevention
- March 8, 2004:** Ischemic Stroke Syndromes: The Challenges of Assessment, Prevention, and Treatment
Part II: Physical Examination, Laboratory Investigations, Imaging, and Treatment
- March 22, 2004:** Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction: An Overview of Current Therapeutic Options
Part I: Pharmacologic Reperfusion
- April 5, 2004:** Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction: An Overview of Current Therapeutic Options
Part II: Mechanical Reperfusion
- April 19, 2004:** Acute Bacterial Rhinosinusitis: Patient Assessment, Risk Stratification, Referral Strategies, and Outcome-Effective Antibiotic Selection, Part I
- May 3, 2004:** Acute Bacterial Rhinosinusitis: Patient Assessment, Risk Stratification, Referral Strategies, and Outcome-Effective Antibiotic Selection, Part II
- May 17, 2004:** Pulmonary Embolism: Recent Advances in Diagnosis and Treatment Modalities
Part I: Epidemiology, Risk Factors, and Pathophysiology
- May 31, 2004:** Pulmonary Embolism: Recent Advances in Diagnosis and Treatment Modalities
Part II: Differential Diagnoses

- June 14, 2004:** Bacterial Skin and Soft-Tissue Infections: A Systematic Approach to Diagnosis and Treatment
Part I: Cellulitis, Furunculosis, and Distal Finger Infections
- June 28, 2004:** Bacterial Skin and Soft-Tissue Infections: A Systematic Approach to Diagnosis and Treatment
Part II: Complicated and Serious Infections
- July 12, 2004:** Respiratory Disease Update 2004: SARS, Influenza, Community-Acquired Pneumonia—The Emergency Medicine Perspective. Part I: SARS and Influenza
- July 28, 2004:** Respiratory Disease Update 2004: SARS, Influenza, Community-Acquired Pneumonia—The Emergency Medicine Perspective. Part II: Community-Acquired Pneumonia
- August 9, 2004:** The Facial Trauma patient in the Emergency Department: Review of Diagnosis and Management
Part I: Life-Threatening Injury and General Wound Repair
- August 23, 2004:** The Facial Trauma Patient in the Emergency Department: Review of Diagnosis and Management
Part II: Orbital and Nasal Trauma
- September 6, 2004:** The Facial Trauma Patient in the Emergency Department: Review of Diagnosis and Management, Part III: Mandible, Mouth, Ear, and Pediatric Trauma
- September 20, 2004:** Common Ear, Nose, and Throat Disorders Encountered in Emergency Practice: Expeditious Evaluation and Definitive Management. Part I: Otitis Media, Sinusitis, and Related Conditions
- October 4, 2004:** Common Ear, Nose, and Throat Disorders Encountered in Emergency Practice: Expeditious Evaluation and Definitive Management.
Part II: Facial Nerve Palsies and Oropharyngeal Infections
- October 18, 2004:** Acute Abdominal Pain in Special Populations
Part I: Pediatric Patients
- November 1, 2004:** Acute Abdominal Pain in Special Populations
Part II: Elderly, Immunocompromised, and Pregnant Patients
- November 15, 2004:** Hypertensive Disorders of Pregnancy
- December 13, 2004:** Emergency Contraception